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ABSTRACT  
   
CTB-MPR649-684 is a translational fusion protein consisting of the cholera toxin B 
subunit (CTB) and the conserved residues 649-684 of gp41 membrane proximal region 
(MPR). It is a candidate vaccine component aimed at early steps of the HIV-1 infection 
by blocking viral mucosal transmission. Bacterially produced CTB-MPR was previously 
shown to induce HIV-1 transcytosis-blocking antibodies in mice and rabbits. However, 
the induction of high-titer MPR specific antibodies with HIV-1 transcytosis blocking 
ability remains a challenge as the immuno-dominance of CTB overshadows the response 
to MPR. X-ray crystallography was used to investigate the structure of CTB-MPR with 
the goal of identifying potential solutions to improve the immune response of MPR. 
Various CTB-MPR variants were designed using different linkers connecting the two 
fusion proteins. The procedures for over-expression E. coli and purification have been 
optimized for each of the variants of CTB-MPR. The purity and oligomeric homogeneity 
of the fusion protein was demonstrated by electrophoresis, size-exclusion 
chromatography, dynamic light scattering, and immuno-blot analysis. Crystallization 
conditions for macroscopic and micro/nano-crystals have been established for the 
different variants of the fusion protein. Diffraction patterns were collected by using both 
conventional and serial femto-second crystallography techniques. The two 
crystallography techniques showed very interesting differences in both the crystal 
packing and unit cell dimensions of the same CTB-MPR construct. Although information 
has been gathered on CTB-MPR, the intact structure of fusion protein was not solved as 
the MPR region showed only weak electron density or was cleaved during crystallization 
of macroscopic crystals. The MPR region is present in micro/nano-crystals, but due to the 
  ii 
severe limitation of the Free Electron Laser beamtime, only a partial data set was 
obtained and is insufficient for structure determination. However, the work of this thesis 
has established methods to purify large quantities of CTB-MPR and has established 
procedures to grow crystals for X-ray structure analysis. This has set the foundation for 
future structure determination experiments as well as immunization studies. 
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CHAPTER 1 
INTRODUCTION 
1.1 The fusion protein CTB and MPR 
HIV and AIDS 
 
Human immunodeficiency virus (HIV) shown in Figure 1.1, is the causal agent of 
acquired immune deficiency syndrome (AIDS). The virus targets cells expressing CD4 
receptors, namely CD4
+
 T cells and some dendritic cells and macrophages that also 
express CD4.  As CD4
+
 T cells are inactivated and killed during the course of the 
infection, the number of CD4
+
 T cells decreases and causes a gradual deterioration of the 
immune system that eventually leads to AIDS. The disease is characterized by a 
susceptibility to infection with opportunistic pathogens and the development of cancer at 
the end stages of the disease. 
 HIV remains as one of the leading causes of death worldwide. In 2012 there were 
an estimated 35.3 million infected individuals, with 2.3 million new infections, and 1.6 
million AIDS related death (UNAIDS, 2013). Although the advancements in 
antiretroviral therapies and access to treatment has curbed the growth of infections in 
many areas, it is clear that the HIV/AIDS pandemic will continue until an effective 
pathway of preventing viral infection and transmission is found. 
 There are currently no cures or working vaccines for HIV. There are several 
factors that make HIV treatment difficult such as the rapid reproduction, the ability to 
persist in a latent form as a transcriptionally silent provirus and the high antigenic 
variability resulting from the high mutation rates in HIV-1. The cause of the high  
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mutation rate is often attributed to the low fidelity of the viral reverse transcriptase 
(Roberts et al., 1988, Preston et al., 1988). The virus evolves by the high variability  and 
selective proliferation of mutant viruses that are both resistant to antiviral drugs and have 
the ability to escape recognition by the immune system then followed by the outgrowth of 
these variants (Murphy et al., 2008). So far, the majority of the drugs developed have 
only been targeting and inhibiting the reverse transcriptase and protease and the 
combination therapy of using multiple drugs together have been shown to be more 
effective than using a single drug (Gortmaker et al., 2001, Murphy et al., 2008). 
Figure 1.1: Illustration of the HIV-1 HIV is a retrovirus that contains an RNA 
genome which is reverse transcribed into DNA in the infected cell by viral reverse 
transcriptase and integrated into the host-cell DNA with the viral integrase. A viral 
protease is involved in the processing of many viral proteins. Two envelope 
glycoproteins gp120 (yellow) and gp41 (red) form the “spikes” on the surface of the 
HIV and have shown to play significant role in viral infection.  Image adapted from 
(Murphy et al., 2008) 
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Therefore an effective treatment or vaccine for HIV should consist of multiple 
components that target various steps of the transmission and infection processes of HIV 
expanding beyond the current drug target. It is especially important  to target the early 
stages of the viral cycle to take advantage of viral vulnerabilities of the low founder viral 
population, lower number of variants and to minimize the establishment of systematic 
infection (Haase, 2010). 
 
Membrane proximal region of envelope glycoprotein 41 in HIV-1 
 
The envelope proteins (Env) and the viral surface proteins of HIV have been one of the 
major focuses of research and development for drugs and vaccines against HIV.  The env 
gene codes for a precursor glycoprotein known as gp160, which is later processed by 
protease cleavage to form gp120 and gp41 (numbers in the names correspond to the 
molecular weight of the protein). The “surface subunit” gp120 is exposed on the exterior 
of the viral envelope and associates, non-covalently, with the “transmembrane subunit”  
gp41 that contains an ectodomain largely responsible for the trimizeration of the Env 
(Wyatt & Sodroski, 1998). Together, the two glycoproteins form the protrusion on the 
virion that are often referred to as “spikes” and are involved in essential steps in the viral 
transmission and infection processes (Murphy et al., 2008).  Env is heavily glycosylated 
with the vast majority of the highly variable glycans attached to gp120 and only few are 
found on gp41 (Wang et al., 2013, Leonard et al., 1990). 
 The gp120 subunit is very immunogenic and had been the main target of vaccine 
research during the first two decades of HIV exploration since its discovery (Zolla-
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Pazner, 2004). However, the heavy glycosylation of gp120, its ever-shifting glycosylation 
patterns and the particularly high mutation rate of HIV virus leading to high variability of 
the protein sequence are undoubtedly major contributing factors in the immune-evasion 
strategy of the virus, making gp120 less than ideal immunogen (Jeang, 2007, Steckbeck 
et al., 2011, Montero et al., 2008).  
 In contrast to gp120, the amino acid sequence of gp41, is more highly conserved, 
indicating that the structural and functional attributes of gp41 are under more exacting 
selective pressure than those of the gp120 (Soudeyns et al., 1999, Bouvin-Pley et al., 
2014, Travers et al., 2005).  Indeed, gp41 has several regions that are crucial to viral 
functions identified to be potential drug targets against HIV-1 (Zolla-Pazner, 2004). One 
of these more conserved regions of gp41 is the membrane proximal external region 
(MPER662–684), which has been known to play a key role in viral fusion with host cells 
(Buzon et al., 2010, Cai et al., 2011) and is also the site the few broadly neutralizing 
monoclonal antibodies (Abs) discovered to date such as 2F5, 4E10, and 10E8 (Zwick et 
al., 2001, Zolla-Pazner, 2004, Huang et al., 2012). 
 Over 90% of global HIV-1 transmissions occur across mucosal surfaces, for 
example through the mucosa lining of the genital and lower intestinal tracts during sexual 
transmission or oropharyngeal mucosa in breastfeeding (Kresina & Mathieson, 1999, 
Overbaugh et al., 1999). The mucosal surfaces of the cervix, rectum and colon are 
characteristically lined by a single layer of epithelial cells that are joined by tight 
junctions, preventing, when intact, the passage of HIV-1 between the cells. Instead, the 
virus co-opts the cellular process known as transcytosis to cross through the cells 
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(without infecting them). Once passed across the epithelial barrier, the virus is likely to 
encounter its target CD4
+
 host cells. 
 The transcytosis process depends on a 36-amino acid-long domain of gp41 
encompassing the MPER and extending partially into the C-terminal heptad repeat 
domain lying immediately upstream to it (residues 649-684). We term this extended-
MPER region “MPR” (also referred to as the P1 peptide in previously published 
work)(Alfsen & Bomsel, 2002, Alfsen et al., 2005). MPR was shown to be crucial for the 
viral crossing of the epithelial membrane (Alfsen & Bomsel, 2002, Zolla-Pazner, 2004, 
Matoba et al., 2004). The domain is vital for the viral epithelial transcytosis of HIV using 
a non-fusogenic mechanism by binding to the glycosphingolipid galatosylcermide 
(GalCer) and the heparan sulfate proteoglycan agrin on the apical surface of epithelial 
cells to initiate endocytosis and transcytosis (Bomsel, 1997, Alfsen et al., 2001, Alfsen & 
Bomsel, 2002, Alfsen et al., 2005). This is significant as it is the first step in one of the 
principle route of HIV infection.  If the virus can be prevented from entering the body to 
reach its host cell this early in the transmission process, the chances of the virus 
establishing a chronic infection would be lowered. 
 Support for the above notion comes from studies conducted with highly HIV-
exposed persistently seronegative (HEPS) individuals. HEPS, are people with high 
exposure risk to HIV, who despite documented high potential for exposure to the virus 
(e.g. multiple and frequent unprotected sexual activities) still remain negative for anti-
HIV serum IgG and lack of detectable HIV RNA or DNA (Devito et al., 2000a, Fowke et 
al., 1996). Still, a subset of these HEPS exhibit gp41-specific secretory IgAs in their 
genital secretions. These antibodies were shown to be efficient in blocking viral 
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transcytosis across the epithelium and were suggested to be correlated to their protection 
against HIV infections (Devito et al., 2000c, Devito et al., 2002, Tudor et al., 2009, 
Miyazawa et al., 2009). These findings suggest that an HIV-1 vaccine component that 
consists of an immunogen that is mucosally targeted and capable of eliciting Abs against 
MPR which can both block the epithelial transcytosis process and neutralize the infection 
of CD4
+
 cells could be relatively effective. MPR was also shown to be able to bind to 
dendritic cells, an important class of antigen presenting cell (Bomsel & Magerus-
Chatinet, 2004, Magerus-Chatinet et al., 2007). Interaction with antigen presenting cells 
is beneficial to elicit immune response against the peptide.  
 
 
 
 
 
 
Figure 1.2: Schematic diagram of the part of the HIV-1 env gene that encodes for 
the gp41 portion. Fusion peptide (FR. Residues 512-539); fusion peptide proximal 
region (FPPR residues 528–539; N-terminal heptad-repeat region (NHR, residues 
540–590); C-terminal heptad-repeat region (CHR, residues 628–661); membrane 
proximal external region (MPER, residues 662–684); membrane proximal region 
(MPR, residues 647–684, blue), transmembrane domain (TM, residues 685–705); 
cytoplasmic C-terminal domain (CTD, residues 706–856). The epitopes of 2 broadly 
neutralizing antibodies 2F5 and 4E10 are marked. 
 
  7 
Cholera toxin B subunit as mucosal adjuvant 
 
The MPR peptide by itself is a rather poor immunogen (Denner, 2011). To boost the 
immunogenicity at the mucosal surface, an adjuvant is needed to enhance the immune 
response of MPR. Cholera toxin B subunit (CTB) was chosen as the candidate to be the 
fusion partner. 
 Secreted by Vibrio cholera, the cholera toxin is a protein complex that is 
responsible for many of the symptoms of cholera infections. It is an oligomeric protein 
made up of six subunits, a single A subunit and five copies of B subunit that form a 
pentameric ring around the tail of the A subunit.  The primary function of CTB is to serve 
as a delivery system for the A subunit. In the intestines, pentameric CTB binds to the 
pentasaccharide moiety of GM1 gangliosides on the mucosal (luminal) side of epithelial 
cells. The AB5 complex is internalized through endocytosis followed by the release of the 
A subunit through the cleavage of disulfide bonds (Merritt et al., 1994). 
 Many immunological studies have been done on using CTB as a mucosal 
adjuvant and as a carrier for foreign peptide epitopes (Quiding et al., 1991, Peltola et al., 
1991, Malley et al., 2004, Qu et al., 2005). The fusion protein retains the important 
structural and functional characteristics of the native CTB such as the pentamerization 
and binding to the GM1 ganglioside receptors (Holmgren et al., 1993, Sun et al., 1994). 
CTB has also been used successfully to produce human vaccines against cholera itself 
(Quiding et al., 1991) and a vaccine against enterotoxigenic Escherichia coli (Peltola et 
al., 1991). It also proved to be a good adjuvant in immunizing mice against Streptococcus 
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pneumonia (Malley et al., 2004) and the severe acute respiratory syndrome-associated 
coronavirus (SARS) (Qu et al., 2005). CTB fusion protein has also been used to elicit 
anti-HIV-1 Abs before, namely the V3 domain of gp120 using V3-CTB fusion proteins 
although was not successful in acting as an effective vaccine against HIV-1 (Backstrom 
et al., 1994, Zolla-Pazner et al., 2011). 
 These findings suggested that CTB may be a suitable adjuvant for the purpose of 
eliciting anti-MPR Abs and can serve as a carrier and for the enhancement of the immune 
response that targets the mucosal membrane. Fusion proteins consisting of CTB and 
MPR649-684 were created (named CTB-MPR). The proposed mechanism of CTB-MPR 
inducing the production of IgA against MPR649-684 of gp41 in the mucosal immune 
Figure 1.3: Space-filling model of cholera toxin. Cholera toxin is an oligomeric 
complex made up of six protein subunits. One single copy of subunit A and five 
copies of subunit B. Subunit A has two important segments, A1 (red) is a globular 
enzyme, while A2 (orange) is an alpha helical chain that fits in the center of the five 
subunit B ring (blue) (Goodsell, 2005). 
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system is shown in Figure 1.3.  In published experiments of Matoba and co-workers, 
CTB-MPR has been shown to elicit HIV-1 transcytosis blocking Abs (Matoba et al., 
2004, Matoba et al., 2006). However, not all trials had successfully shown anti-
transcytosis activity and the titer of MPR specific antibodies caused by CTB-MPR 
remained low.  Subsequent booster immunizations in rabbits with CTB-MPR did not 
result in further improvement of the anti-MPR Ab responses because anti-CTB Abs 
continued to increase and thereby overshadowed the response to MPR (Matoba et al., 
2008). This indicated a need for the improvement of the MPR-based immunogen. 
 
 
 
 
 
Figure 1.4: Proposed mechanism of the fusion protein of CTB-MPR The 
pentameric CTB domain binds to GM1 gangliosides after which the fusion protein 
complex is taken up by the cell via endocytosis as a whole. The complex is then 
presented to antigen presenting cells which promotes a T helper cell response that 
signals B cells to produce Abs against the presented antigen, in this case MPR. 
(Adapted from N. Matoba) 
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Motivations and objectives 
 
To understand the function of MPR and the membrane associated processes it is involved 
in, such as the epithelial transcytosis and the membrane fusion to the host cells, as well as 
interactions with the immune system, it is imperative to obtain the structural information. 
The molecular structure defines the properties and function of proteins as well as their 
complex macromolecular assembles (Rupp, 2010). Part of the structure of gp41, that may 
represent the post-fusion state of gp41 after the virus has fused with the host cell, has 
been solved by X-ray crystallography. It formed a six helices bundle of a trimer with each 
domain of gp41 containing two anti-parallel helices shown in Figure 1.5A (Chan et al., 
1997, Melikyan et al., 2000). However, these structures provided only limited 
information for understanding of the structure-function relationship of gp41 as they 
contained only part of the MPER domain and the sites of the broadly neutralizing Abs 
(2F5, 4E10 and Z13) were buried inside the bundle of helices and were not exposed for 
Ab access shown in Figure 1.5B and 1.5C (Shi et al., 2010, Buzon et al., 2010). It was not 
until recently, when there has been published work on a proposed ‘pre-fusion’ 
conformation of gp41. A ‘pre-fusion’ NMR dynamics study showed structures that 
contained large portions of gp41, however it is questionable if these structures really 
represent a “pre-fusion” conformation as they are similar to the two anti-parallel helices 
conformation reported previously for the post fusion conformation (Lakomek et al., 
2014). Another NMR structure of pre-fusion state included MPER attached to a 
trimerization domain of bacteriophage T4 fibritin foldon domain that forces the MPER in 
a conformation in which the Ab sites are accessible was solved recently and is shown in 
  11 
Figure 1.5D (Reardon et al., 2014). Interestingly, the gp120 and gp41 crystal structure 
shown in Figure 1.5E showed a different conformation. In this structure, gp41 is arranged 
in a four helices collar that is very different from the two anti-parallel helices. However 
the part of gp41 used for this structural study did not contain the MPER domain that bind 
the neutralizing Ab epitopes (Pancera et al., 2014). The structures from these publications 
also differ from each other, making it difficult to determine which (if any) would 
represent the native pre and post fusion conformation of gp41. 
 CTB-MPR has shown promising results in inducing anti-HIV Abs that could 
block transcytosis, thereby hinting that the Ab sites are exposed in CTB-MPR; it would 
be very important for further improvement of CTB-MPR as a potential vaccine against 
HIV to determine the structure of MPR in its CTB-MPR fusion conformation as none of 
the published structures of gp41 may represent the immunogenic form of MPR. 
 The unraveling of the structure of CTB-MPR would surely help in improving the 
vaccine design as CTB-MPR has shown already promise in anti-HIV activities. To 
achieve this goal, we have decided to pursue the path of protein X-ray crystallography for 
structure determination. 
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Figure 1.5: Published gp41 and MPER structures. The structures were obtained 
from the PDB and the pictures were generated by PyMol (Delano, 2002). (A)  PDB 
ID: 1AIK. Structure of gp41 post fusion 6-helices bundle that only contained the 
helices NHR and CHR (Chan et al., 1997) (B) PDB ID: 2X7R. Structure of gp41 6-
helices bundle that also included parts of FPPR and MPER (Buzon et al., 2010) (C)  
PDB ID: 3K9A. Structure of gp41 6-helices bundle that included overhanging MPER 
without the FPPR (Shi et al., 2010) (D) PDB ID: 2LP7. NMR structure of MPER 
linked with the foldon domain of bacteriophage T4 fibritin (Reardon et al., 2014) (E) 
PDB ID: 4TVP. Structure of gp120 and gp41 pre-fusion confirmation with gp41 
arranged in a 4-helices collar (MPER not included) (Pancera et al., 2014) 
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1.2 X-ray Protein Crystallography 
Overview and theory 
 
The structure and function of molecules are related to each other at the atomic and 
molecular level. Therefore, in order to completely understand the properties and 
functions of proteins and their interaction with other molecules, it is necessary to 
determine their structure. Nearly 100,000 protein structures have been solved and 
deposited in the protein database (PDB) by X-ray crystallography, nuclear magnetic 
resonance (NMR), electron microscopy (EM), with the vast majority (~90%) of the 
structures determined by protein X-ray crystallography. 
 In conventional x-ray crystallography, a single crystal is placed into a finely 
focused x-ray beam and the x-rays scattered by the electrons of the atoms in the crystal 
are recorded as diffraction patterns by a detector. The diffraction patterns are analyzed by 
X-ray structure analysis. The amplitude of the structure factors is determined from the 
intensity for the reflection, the wavelength corresponds to the wavelength of the X-ray 
beam but phase information for each structure factor is lost and has to be solved by 
molecular replacement (for homologous structures) or de-novo by MIR (multiple 
isomorphous replacement), MAD (multiple anomalous dispersion) or SAD (single 
anomalous dispersion). After retrieval of the phases, the electron density of the 
crystallized protein is reconstructed. An atomic model fitting the electron density is built 
using computational methods and refined into the resultant protein structure (Woolfson, 
1997, Rupp, 2010). Although it may appear quite straightforward and simple, there are 
various challenges that must be overcome to obtain a crystal structure. 
  14 
 When an X-ray photon strikes an atom, it interacts with the electron cloud of the 
atom and is either absorbed or scattered. The scattering from a single protein molecule by 
the X-rays is too small to be measured with the current technology (Glaeser, 1999, 
Spence & Doak, 2004). In order to increase the signal to detectable levels, it requires the 
protein to be arranged in an orderly three-dimensional repeating lattice of equivalent unit 
cells to amplify the signal (Figure 1.6). The amplification can be of the order N
2
, where N 
is the number of unit cells in the crystal (Miao et al., 2004). 
 Bragg’s Law describes the coherent scattering of light (in this case x-rays) from a 
crystal lattice (Figure 1.7): 
2d sin θ = nλ 
where d is the distance between the reflective planes, θ is the angle of incidence of the x-
ray which will reflect back with a same angle of scattering, n is an integer, and λ is the 
wavelength of the X-ray. When X-rays strike a protein crystal, the waves are scattered 
from the planes separated by a distance d. The waves will interfere constructively and 
destructively depending on the path difference between the two waves 2d sin θ. The 
waves that remain in phase (a phase shift that is a multiple of 2π) will interfere 
constructively resulting in measureable reflections.  Scattering from each set of planes in 
a crystal leads to a reflection which corresponds to a structure factor in the reciprocal 
space. 
 In order to reconstruct the electron density of the scattering molecule, the Fourier 
reconstruction from reciprocal diffraction space of the diffraction pattern back into a 
three-dimensional direct molecular space is needed (Rupp, 2010). However, to carry out 
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Fourier transform, the properties of the scattered X-rays are needed in order to 
reconstruct the wave; wavelength, amplitude and phase angle. The wavelength of the 
scattered X-rays is the same as those the crystal is exposed to. The amplitude is equal to 
Figure 1.6: Unit cell and crystal. A unit cell is the smallest unit of a repeating lattice 
that contains the structure and symmetry information. A crystal is an ordered 3-
dimensional repeating array of unit cells. 
Figure 1.7: Bragg’s Law The graphical interpretation of Bragg’s Law shows 
conditions for the constructive interference of the X-ray diffraction from the reflective 
planes of a crystal. 
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the square root of the intensity the diffraction spot (reflection) and can be calculated 
based on the measured intensities (Rupp, 2010). The phase angle, which contains most of 
the structural information, is lost in the measurement and is not readily available; its 
value must be determined by other experiments. This is known as the phase problem and 
is a reason why protein structure determination can be quite difficult. 
 There are several ways to solve the phase problem. The brute force direct method 
exploits the phase relations between certain sets of structure factors, but it is limited to 
only relatively small proteins (Rupp, 2010). Another method is using marker atoms such 
as heavy atom derivatives and comparing it to the native crystal diffraction to produce a 
difference map to calculate phase (Woolfson, 1997, Rupp, 2010). The introduction of 
heavy metal atoms is typically done by either soaking the crystal in heavy metal solution 
or introducing marker atoms such as selenium in form of selenomethionine during 
expression of the protein in-vivo. The methods summarized above allow for de-novo 
structure determination and they do not require prior structure information.  A third 
method, molecular replacement requires a structurally similar model as a molecular 
probe. By using a previously solved structure homologue of the crystallized protein,  the 
phases of the correctly placed models are used as starting phases for map reconstruction 
(Rupp, 2010). 
 Once the electron density map is calculated, a model must be generated to fit the 
electron density, and then further refined. As each atom of the structure contributes to all 
of the diffraction spots in a nonlinear way, it is necessary to adjust the model parameters 
to best describe the data. Stereochemical knowledge must generally be incorporated into 
the refinement in the form of restraints to keep the model within reasonable bounds. 
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Protein crystallization 
 
In order to obtain a high resolution X-ray structure, a well-diffracting protein crystal is 
required. The scattering of X-rays is dependent on the atomic number of the atoms in the 
protein, which corresponds to the number of electrons; the higher the number, the greater 
the scattering intensity (Woolfson, 1997). However, biological macromolecules are 
mainly comprised of H, C, N, O, and small amount of S and P. These are atoms with 
relatively low atomic numbers and low scattering intensity. In addition, the native states 
of proteins are typically not at solid state but they are surrounded by a fluid environment 
such as an aqueous solution. It is common for proteins to have a solvent content between 
30% and 70%, and even in some cases up to 90% have been reported (McPherson, 2004) 
creating large unit cells with few crystal contact sites (Rupp, 2010). Therefore, in order to 
obtain high resolution diffraction, large protein crystals are necessary due to the weak 
scattering of the elements and the relatively high solvent content of the unit cell. 
 The first step of protein crystallization is the preparation of the protein in 
quantities needed for crystallization experiments.  Through recombinant DNA 
engineering, it is possible to overexpress proteins that are synthetically designed or not 
abundant in nature in bacterial or eukaryotic cells (Rupp, 2010). However, the 
purification remains a great challenge as high purity samples are required for 
crystallization.  For crystallography, the concept of purity does not only mean the 
removal unrelated proteins or other undesired cellular components, but also means 
maintaining the protein in homogenous form in a single conformation and an unique 
oligomeric state.  The presence of contaminants and different conformations or a 
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heterogeneity of oligomeric states may hinder crystal growth in a number of ways. 
Different forms of the same protein may compete for crystal contacts thereby generating 
lattice errors leading to mosaicity, dislocation, irregular faces and secondary nucleation, 
twinning, poor diffraction, and ceasing crystal growth (Ducruix & Giegé, 1992). To 
probe the purity and homogeneity of protein samples, many different techniques such as 
electrophoresis, gel filtration, and light scattering methods are used to detect 
contaminants or structural oligomers based on charge, size, mobility and shape (Ducruix 
& Giegé, 1992, Rupp, 2010). 
 Many crystallographers consider protein crystallization to be more of an art than 
science. It is the least understood step of structure determination of a protein as there is 
no known method of predicting exactly under what conditions a protein will form crystals 
(Rupp, 2003). The effects of buffers, salts, pH, detergents, temperature, precipitant, and 
additives may all have drastic and unpredictable effects on protein crystallization. 
Therefore, the number of possible crystallization conditions far exceeds the number that 
may be reasonably tested. Techniques such as the grid screens described in (McPherson, 
1982), factorial designs (Carter & Carter, 1979), and sparse matrix sampling (Jancarik & 
Kim, 1991) have been developed. They sample many conditions that have been 
previously reported to lead to crystallization of proteins. However, none of the 
commercial screen systematically investigates the influence of each of the crystallization 
factors so that the effects of each factor can be determined as there is a limit to the total 
number of crystallization conditions that can be explored per screen. Many commercial 
crystallization screens are based on these screening techniques and have been widely 
used. 
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 Once initial crystallization conditions are found, it is still necessary to further 
improve the crystal quality in finer screens that screens around the condition that had led 
to crystal hits in commercial screens by adjusting the concentrations of the components in 
the crystallization cocktails. 
 The main objective in protein crystallization is to reach the supersaturated phase 
to coerce the protein out of the solution gently into a well-ordered lattice. The protein 
solubility is typically reduced by various methods such as the addition of precipitate to 
the protein solution, removal of water from the protein-precipitate solution through vapor 
diffusion, exchange of solvent through dialysis; change of pH, or by use of free interface 
diffusion. The protein solution becomes supersaturated and when the nucleation zone is 
reached crystals may form correlating to the schematic phase diagram shown in Figure 
1.8 (Ducruix & Giegé, 1992, Chayen & Saridakis, 2008, Rupp, 2010). During a 
crystallization experiment, crystals do not appear as soon as the supersaturated phase is 
reached. The crystallization process is not only determined by the thermodynamics but 
also by the kinetics pf the system. It is very common that no crystals are formed in the 
supersaturated zone due to kinetic barriers. Nuclei form and dissolve; the size and 
stability of nuclei depend on the supersaturation. In the metastable zone the nuclei are too 
small to be stable, therefore crystals cannot form but pre-grown seeding crystals can 
grow. Once the nucleation zone is reached and activation barriers toward equilibration 
are overcome, a nucleation event occurs that leads to formation of nuclei that exceed the 
critical radius, leading to stable nuclei which can further grow into a crystal. By crystal 
growth the protein concentration in the solution decreases until the supersaturation 
borderline is reach. Crystals are not always formed in a crystallization experiments, often 
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amorphous precipitate is observed instead of crystals.  The reason are manifold and 
include but are not limited to very high supersaturation, unsuitable conditions for the 
formation of crystal contacts, partial or complete denaturation of the protein by the 
supersaturated conditions, flexible domains of the protein prohibit formation of crystal 
contacts, high dynamics of protein hinder formation or an ordered lattice etc.  
 
 
 
Figure 1.8: Basic solubility phase diagram shows the general observation of 
crystallization. The higher the precipitant concentration, the lowers the maximum 
concentration for the protein to achieve each phase and vice versa. Between the 
solubility line and instability line are the metastable and nucleation zones. The 
metastable zone represents a supersaturated protein solution where pre-formed crystal 
can grow but no stable nuclei are formed. In the nucleation zone nuclei are stable and 
crystals are observed. 
  21 
 Though high supersaturation is necessary for the nucleation, it is not desirable for 
the growth of large, well-ordered single crystals. A high supersaturation promotes the 
formation of large numbers of nuclei leading to the growth of many protein microcrystals 
rather than the macroscopic crystals required for conventional protein crystallography, 
where data are collected from single crystals at synchrotron sources. In addition, at very 
high supersaturation, the protein will precipitate in form of unordered amorphous 
precipitates as mentioned previously. While the formation of protein crystals are 
thermodynamically favored in supersaturated conditions, the amorphous precipitates are 
kinetically favored under high supersaturation conditions (McPherson et al., 1995). 
 
Serial femtosecond X-ray crystallography 
 
One difficulty with protein crystallography is that crystal growth of protein microcrystals 
is much more common than the growth of macroscopic protein crystals necessary for data 
collection at conventional X-ray sources (synchrotrons or rotating anodes) (Cusack et al., 
1998).  Also, large crystals often suffer from the long range internal disorder or 
mosaicity. Protein crystals are made up of small mosaic blocks, with each block being 
well ordered in submicrons dimensions, but the gaps between the blocks create angular 
misalignments. This long range disorder reduces the intensity and broadens the 
diffraction spots (Woolfson, 1997). So there are advantages of using smaller crystals with 
the trade-off of having weaker scattering intensity. These weaker intensities can only be 
partially enhanced by an increase in X-ray intensity due to the X-ray damage problems in 
crystallography (Owen et al., 2006, Barty et al., 2012). The micro-focused beamlines at 
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third generation Synchrotron sources, where the beam is focused to 5-25 micrometer size, 
alleviate some of the weak scattering intensity problem by reducing the focus spot radius 
and increasing the flux density at the spot (Bilderback et al., 2003, Bilderback et al., 
2010). However, this leads to higher radiation damage and limits the lifetime of the 
crystal for data collection. 
 With the technology advancement and the introduction of the X-ray free electron 
laser (XFEL), a new approach to collect diffraction data from much smaller crystals 
became possible. The XFEL is able to generate a peak X-ray flux that is 10
9
 higher than a 
3rd generation synchrotron pulse and allows data collection from crystals that contain just 
a few hundred molecules (Barty et al., 2009, Fromme & Spence, 2011, Chapman et al., 
2011). The method, serial femtosecond X-ray crystallography (SFX), is based on the 
“diffract before destroy” principle. By using short 10-50 fs pulses of X-ray exposures, the 
diffraction of a nano/microcrystal could be recorded before the molecules in the crystal 
are destroyed and the crystals disintegrate (Barty et al., 2012). As the beam destroys the 
sample, fresh new sample is continuously delivered across the pulsed beam in the form of 
a liquid jet of nano/microcrystals in their mother liquor at ambient temperature, leading to 
hundreds of thousands of diffraction snapshots of individual crystal in random 
orientation. SFX eliminates the radiation problem suffered from micro-focused beam data 
collection at Synchrotrons as each snapshot is collected from a fresh crystal. The general 
scheme of SFX is illustrated in Figure 1.9. 
 Data analysis for SFX is a challenge. The diffraction gathered at synchrotrons, 
depends on a systematic continuous rotation of the crystal by a goniometer, where all 
planes of the crystal are systematically brought into conditions for diffraction. Thereby it 
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allows for the angular integration across all Bragg reflections. In contrast the SFX 
snapshot diffraction patterns are all random “still image” which sample a random slice 
through the Ewald sphere. Furthermore, the SFX beam shows larger intensity variations 
(of a factor of 4) and the energy profiles are not identical between individual X-ray 
pulses. Therefore structure determination by SFX requires a larger multiplicity of the data 
sets (Fromme & Spence, 2011). The merging of thousands or even millions of diffraction 
data poses a large challenge and requires new tools for the integration of the data, where 
the intensity of the individual Bragg reflections are determined by Monte Carlo 
Integration (Kirian et al., 2011).  Although the minimum number of the snapshots 
required is currently unknown and controversially debated, the first near-atomic 
resolution structure of a protein to be determined using SFX contained more than 12,000 
indexed diffraction patterns which is much more than what is needed for conventional 
crystallography (<1,000) at a synchrotrons (Boutet et al., 2012, Chapman et al., 2011, 
Redecke et al., 2013, Liu et al., 2013). 
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Figure 1.9: Serial femtosecond crystallography. Diffraction patterns from single 
crystals flowing in a liquid jet are recorded on Cornell-SLAC Pixel Array Detectors 
(CSPAD). Image adapted from (Boutet et al., 2012) 
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(This chapter has been adapted with permission from a previously published report: Lee, 
H-H et al. Expression, purification and crystallization of CTB-MPR, a candidate mucosal 
vaccine component against HIV-1. IUCrJ 1(Pt 5): 305-317 (2014)) 
 
2.1 Abstract 
 
CTB-MPR is a fusion protein between the B subunit of cholera toxin (CTB) and the 
membrane-proximal region of gp41 (MPR), the transmembrane envelope protein of 
Human immunodeficiency virus 1 (HIV-1), and has previously been shown to induce the 
production of anti-HIV-1 antibodies with antiviral functions. To further improve the 
design of this candidate vaccine, X-ray crystallography experiments were performed to 
obtain structural information about this fusion protein. Several variants of CTB-MPR 
were designed, constructed and recombinantly expressed in Escherichia coli. The first 
variant contained a flexible GPGP linker between CTB and MPR, and yielded crystals 
that diffracted to a resolution of 2.3 Å, but only the CTB region was detected in the 
electron-density map. A second variant, in which the CTB was directly attached to MPR, 
was shown to destabilize pentamer formation. A third construct containing a polyalanine 
linker between CTB and MPR proved to stabilize the pentameric form of the protein 
during purification. The purification procedure was shown to produce a homogeneously 
pure and monodisperse sample for crystallization. Initial crystallization experiments led 
to pseudo-crystals which were ordered in only two dimensions and were disordered in the 
third dimension. Nanocrystals obtained using the same precipitant showed promising X-
ray diffraction to 5 Å resolution in femtosecond nanocrystallography experiments at the 
  27 
Linac Coherent Light Source at the SLAC National Accelerator Laboratory. The results 
demonstrate the utility of femtosecond X-ray crystallography to enable structural analysis 
based on nano/microcrystals of a protein for which no macroscopic crystals ordered in 
three dimensions have been observed before. 
 
2.2 Introduction 
 
The envelope glycoprotein of HIV-1 is a complex composed of three copies of a 
heterodimer consisting of gp120 and gp41. The latter (Figure 2.1a) is embedded in the 
viral membrane, mediates the fusion between viral and cellular membranes (Teixeira et 
al., 2011) and plays a major role in viral transmission across the epithelial barrier (Shen 
et al., 2010, Bomsel et al., 2011, Hessell et al., 2010, Tudor et al., 2009). Mucosal 
transmission of HIV-1 through monostratified epithelia depends on interactions between 
the viral envelope membrane protein gp41 and the glycolipid galactosyl ceramide 
(GalCer) on epithelial cells (Alfsen et al., 2001, Alfsen & Bomsel, 2002, Meng et al., 
2002), and also on dendritic cells, the most important class of antigen-presenting cells 
(Bomsel & Magerus-Chatinet, 2004, Magerus-Chatinet et al., 2007). The GalCer binding 
domain of gp41 is mediated by a highly conserved membrane-proximal region (MPR) of 
gp41 consisting of residues 649–684. This region of the protein spans the membrane-
proximal external region (MPER; residues 660–683) reviewed by (Zwick, 2005), which 
includes the epitopes for the broadly neutralizing and transcytosis-blocking monoclonal 
human antibodies 2F5, 4E10 and 10E8 (Zwick et al., 2001, Huang et al., 2012) and, 
unlike the MPER itself (residues 650–683), maintains important structural and functional 
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attributes of the native protein, including oligomerization and GalCer binding (Alfsen & 
Bomsel, 2002). 
 An effective vaccine against HIV-1 should ideally consist of components that 
target multiple steps of the viral transmission/infection process. Most importantly, it 
should engage the virus early in the cycle to minimize the chance of establishing viral 
reservoirs and subsequent re-dissemination (Valdiserri et al., 2003). From a worldwide 
perspective, HIV-1 transmission most commonly occurs through the exposure of mucosal 
surfaces to HIV-positive secretions (Pope & Haase, 2003, Hladik & McElrath, 2008, 
Haase, 2011). Therefore, the crucial involvement of the MPR in mucosal transmission of 
HIV and the well characterized, albeit rare, antiviral immune responses directed against 
this domain make it a prime candidate for an active vaccine. 
 However, by itself, the MPR was shown to act as a rather poor immunogen and 
was sensitive to its structural context (Denner, 2011). To overcome these limitations and 
in particular to boost immunogenicity at the mucosal surface, we have been exploring the 
MPR through its fusion to the mucosa-targeting cholera toxin B subunit, CTB (Matoba et 
al., 2004, Matoba et al., 2006, Matoba et al., 2008, Matoba et al., 2009). The CTB 
pentamer is taken up by mucosal immune cells through endocytosis mediated by binding 
to GM1 gangliosides (Merritt et al., 1994). Thus, a fusion protein comprised of CTB and 
MPR provides the target epitopes needed to elicit anti-HIV-1 antibodies directed at the 
MPR and combines the mucosal targeting of CTB and its immunogenicity. However, 
anti-MPR responses elicited by CTB-MPR were not optimal and indicated a need for an 
improved MPR-based immunogen (Matoba et al., 2004, Matoba et al., 2006, Matoba et 
al., 2008, Matoba et al., 2009, Matoba et al., 2011). 
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 Understanding the function of MPR and the membrane-associated processes it 
takes part in, such as transcytosis and membrane fusion, as well as its interactions with 
the immune system, requires knowledge of its structure. To better understand the 
immunogenicity of the fusion protein and to enable us to design even more immunogenic 
Figure 2.1: gp41 and CTB-MPR variants (a) The architecture of gp41. FP (residues 
512–527), fusion peptide; FPPR (residues 528–539), fusion peptide proximal region; 
NHR (residues540–590), N-terminal heptad-repeat region; CHR (residues 628–661), 
C-terminal heptad-repeat region; MPER (residues 662–684), membrane-proximal 
external region; MPR (residues 647–684, hatched), membrane-proximal region; TM 
(residues 685–705), transmembrane domain; CTD (residues 706–856), cytoplasmic C-
terminal domain. (b,c,d) DNA constructs for the expression in E.coli of the indicated 
CTB-MPR fusion proteins are based on elements of the pET-22b expression vector. P, 
T7 bacteriophage promoter; 5’-UTR, upstream untranslated region; pelB, the 
periplasmic targeting sequence of pectate lyase B of Erwinia carotovora; CTB, 
cholera toxin B subunit; MPR, the membrane-proximal region of the gp41 protein of 
HIV-1; 3’-UTR, downstream untranslated region; T, T7 terminator. The GPGP and 
AAAA linkers are indicated above their respective constructs. The three constructs 
encode the fusion proteins CTB
GPGP
MPR (b), CTBMPR (c) and CTB
AAAA
MPR (d) 
with expected molecular masses (after the processing of the pelB leader sequence) of 
16.7, 16.4 and 16.7 kDa, respectively. 
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MPR fusion proteins, we turned to structural investigation. Here, we report on the 
expression of several novel variants of CTB-MPR with different linkers between the two 
fusion partners. We further report the purification of these proteins and their biochemical 
characterization, as well as initial crystallization experiments and X-ray crystallographic 
analysis. 
 
2.3 Materials and methods 
Vectors for bacterial expression of CTB-MPR fusion protein variants 
 
The expression vectors used in this study were all based on the Escherichia coli 
periplasmic targeting vector pET-22b(-) (Novagen; Figure. 2.1b, 2.1c and 2.1d). The 
cloning of a synthetic gene encoding a fusion protein comprising CTB and the MPR with 
a flexible GPGP linker between them to obtain the plasmid pTM101 has been described 
previously (Matoba et al., 2004). To obtain a fusion protein without the C-terminal His 
tag engineered on the protein product of pTM101, we PCR-amplified the coding 
sequence with primers oTM066 and oTM123 (see Table 2.1 for a complete list of the 
oligonucleotides used in this work), and following digestion with NcoI and BlpI cloned 
them into the respective sites in the pET-22b(-) vector to obtain pTM199. In this work, 
the fusion-protein product of this vector is called CTB
GPGP
MPR. 
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Table 2.1: Oligonucleotides used as primers in this study 
No. Name 5’-Sequence-3’ 
1 oTM066 AGCCATGGGCACCCCACAAAACATCACTG 
2 oTM123 ATTGCTCAGCGGTTCAGATCTTGATATACCAAAGC 
3 oTM468 GGCAAATTCCCAAACCCAACAAGAGAAGAATG 
4 oTM469 CTTGTTGGGTTTGGGAATTTGCCATGCTAATGGCAGC 
5 oTM521 GCGGCCGCGGCCTCCCAAACCCAACAAGAG 
6 oTM522 GGCCGCGGCCGCATTTGCCATGCTAATGG 
 
  
 The plasmid pTM199 served as the template to construct two additional variants 
of the fusion protein by overlap PCR (Aiyar et al., 1996). Briefly, in two separate PCR 
reactions, the two ‘end’ primers oTM066 and oTM123 were used, respectively, with two 
‘mutagenizing’ primers oTM469 and oTM468 to amplify two partially overlapping 
fragments of the coding region of the fusion gene. The two fragments, now containing the 
deleted linker region, were gel-purified and used together as templates with the ‘end’ 
primers to PCR-amplify the complete fusion gene. The fragment was cloned into a 
pTOPO-TA vector (Invitrogen) to yield pTM545, and the correct sequence was verified. 
An NcoI–BlpI fragment from pTM545 was cloned into the corresponding sites of a pET-
26b(+) vector to yield pTM556. The periplasmic-directed, linker-less version of the 
fusion protein encoded by this vector is referred to here as CTBMPR. A similar strategy 
(employing the ‘end’ primers oTM066 and oTM123 together with the ‘mutagenizing’ 
primers oTM522 and oTM521) was used to create a vector, pTM646, encoding a variant 
fusion protein with a tetra-alanine linker dubbed CTB
AAAA
MPR. 
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Expression and purification of fusion-protein variants 
 
Bacterial expression of CTB-MPR fusion-protein variants followed our previously 
published protocol for the CTB
GPGP
MPR variant (Matoba et al., 2008). Similarly, we 
have modified the previously published purification protocol (Matoba et al., 2008) to 
avoid precipitation of the protein at high pH and to replace the previously used detergents 
with detergents that would be compatible with crystallization. Briefly, cell pellets from 2 
l culture (approximately 5 g) were resuspended in 20 ml ice-cold phosphate-buffered 
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) 
containing 1 mM phenylmethanesulfonyl fluoride (PMSF), a serine protease inhibitor, to 
prevent protein degradation. The cells were lysed by passing them twice through a 
microfluidizer (Microfluidics Microfluidizer) with PMSF added again after the first pass. 
The lysate was collected in a 40 ml Oak Ridge tube and was centrifuged at 36,000 g for 
20 min. The insoluble fraction was washed once by repeated resuspension (in 30 ml ice-
cold PBS) and centrifugation. If not immediately used, the pellet was frozen at 80°C. 
 The pellet, containing the membrane fraction, was resuspended in 30 ml buffer 
(20 mM bicine pH 8.0, 500 mM NaCl). To fully homogenize the solution, the sample was 
sonicated at 20% amplitude in 30 s runs (Model 300V/T Ultrasonic Homogenizer, 
Biologics Inc.) until a homogenous turbid suspension was obtained. The detergent n-
dodecyl-β-D-maltoside (βDDM) was used for solubilization. A stock solution of 10% 
(w/v) was added to a final concentration of 1% (w/v). The protein was solubilized at 4°C 
overnight with agitation. 
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 The protein solution was centrifuged at 36,000 g for 20 min and the pellet was 
discarded. A gravity-driven column (Bio-Rad Econo-Column) containing cobalt affinity 
resin (40 ml bed volume; Talon, Clontech) was equilibrated with binding buffer 
(resuspension buffer supplemented with 0.05% βDDM). The sample was then loaded 
onto the column and washed with six bed volumes of binding buffer and ten bed volumes 
of wash buffer (20 mM bicine pH 8.0, 50 mM NaCl, 5mM imidazole, 0.05% βDDM) to 
remove weakly bound proteins. Tightly bound proteins were eluted by the application of 
three bed volumes of elution buffer (20 mM bicine pH 8.0, 50 mM NaCl, 150 mM 
imidazole, 0.05% βDDM). 
 The eluted fractions were pooled and then concentrated to approximately 2 mg 
ml
-1
 using 50 kDa molecular-weight cutoff (MWCO) concentrators (Vivaspin 20 
VS2031, Sartorius Stedim Biotech). Concentrated samples were further purified by size-
exclusion chromatography (SEC; Superdex 200, GE Healthcare; column volume 24 ml, 
fluid phase 8 ml) using a high-pressure liquid-chromatography instrument (HPLC; 
ÄKTAexplorer, Pharmacia). The running buffer consisted of 20 mM HEPES pH 7.5, 10 
mM calcium chloride, 0.02% βDDM. For analytical separations, a sample (200 µl) of 
concentrated CTB- MPR variant was loaded onto the SEC column and chromatography 
was performed at a flow rate of 0.5 ml min
-1
. The column was loaded with a maximum of 
1 ml sample for preparative separation runs, with only slight broadening of the peaks 
being observed. The protein elution was detected by absorption at 280 nm. Fractions 
corresponding to individual peaks were collected and pooled. 
 The concentrations of CTB-MPR variant preparations were determined 
spectrophotometrically (A280) using ɛ280 = 39,380 M
-1
cm
-1
 (ɛ280 was calculated with the 
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ProtParam web application; http://web.expasy.org/protparam/). Assembly of pentamers 
of the CTB-MPR variants was monitored by ELISA using GM1 gangliosides for capture 
and the MPR-specific human monoclonal antibody 2F5 as described previously (Matoba 
et al., 2008) and by nondenaturing SDS–PAGE (see below). 
 
SDS-PAGE and immunoblotting 
 
SDS–PAGE using tricine-based buffers in a Bio-Rad Mini-PROTEAN Tetra Cell was 
performed as previously described by (Lawrence et al., 2011) based on the method of 
(Schagger, 2006) Following electrophoresis, the gels were stained with Coomassie 
Brilliant Blue, subjected to silver staining (Lawrence et al., 2011) or processed for 
immunoblotting. 
 For immunoblotting, the acrylamide gel was rinsed with water and equilibrated in 
anode buffer consisting of 60 mM Tris, 40 mM N-cyclohexyl-3-aminopropanesulfonic 
acid (CAPS), 15% methanol. The PVDF membrane was prepared by soaking in 100% 
methanol and then equilibrated in cathode buffer consisting of 60 mM Tris, 40 mM 
CAPS,0.1%SDS.The gel and the membrane were sandwiched between extra-thick blot 
filter papers (Bio-Rad) soaked in the appropriate electrode buffer and proteins were 
electroblotted for 30 min at 120 mA (Bio-Rad Transfer-blot SD Semi-dry Transfer Cell). 
Following blocking for 1 h in PBSTM (PBS, 0.05% Tween 20, 5% dry milk), the PVDF 
membrane was further incubated in the presence of the 2F5 monoclonal antibody (kindly 
provided by the NIH’s AIDS Reagent Program; 1:10 000 dilution; (Purtscher et al., 
1996)). The membrane was then washed for 3 x 30 min in PBST (PBS, 0.05% Tween 20) 
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prior to incubation (1 h) with rabbit anti-human IgG conjugated to horseradish peroxidase 
(1:20 000 dilution in PBSTM; Santa Cruz Biotechnology sc-2923). Following three 
additional 30 min washes, the PVDF membrane was then soaked with Bio-Rad Clarity 
Western ECL substrate solution and imaged with a UVP BioSpectrum 500C Imaging 
System. 
 CTB forms a very stable pentamer that resists dissociation by SDS in a monomer 
concentration-dependent manner. Nonetheless, CTB pentamers can be denatured by heat 
and by reduction of the intermolecular disulfide bridges that stabilize the oligomers 
(Zrimi et al., 2010, Yasuda et al., 1998). Nondenaturing SDS–PAGE was conducted as 
described above except that DTT was omitted from the loading buffer and the samples 
were not boiled prior to loading them onto gels (Matoba et al., 2008). 
 
Dynamic light scattering 
 
Dynamic light-scattering (DLS) measurements were performed using a NaBiTec GmbH 
setup comprising a SpectroSize 302 (Molecular Dimensions) in combination with an S6D 
microscope (Leica). The purified protein sample (concentrated to 8 mg ml
-1
 as described 
above) was illuminated in a 3 µl hanging drop using a 24-well crystallization plate (VDX 
Greased Plate, Hampton Research) covered with siliconized-glass circular cover slides 
(22 mm; Hampton Research). The well itself was filled with 600 µl SEC running buffer. 
Prior to the measurement, the protein solution was centrifuged (1,000 g, 30min, 4°C) to 
remove possible dust particles. During the measurement, the temperature was set to 20°C. 
Ten consecutive measurements, each with an integration time of 20 s, were averaged. An 
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estimate of the hydrodynamic size was obtained with the instrument software using the 
following parameters: refractive index 1.33, viscosity 1.006, shape factor 1.0, hydrated 
shell 0.2 nm. 
 
Crystallization experiments 
 
For crystallization experiments, the fusion-protein preparations were concentrated to a 
final concentration of 10 mg ml
-1
 using 100 kDa MWCO concentrators (Amicon 
Centricon YM-100). Initial broad screening for crystallization conditions used NeXtal 
crystallization kits (The PEGs Suite, The MB Class Suite and The MB Class II Suite) 
with the vapor-diffusion technique. Screening was performed using 96-well plates 
(Qiagen CrystalEX 96-well Conical Flat Plate) with the sitting-drop method, where each 
reservoir well contained 100 µl precipitant solution. The purified protein solution was 
then mixed in a 1:1 ratio (1 µl:1 µl) with the reservoir solution in the sitting-drop well. 
 Conditions that produced crystals served to guide us in fine screening by the 
hanging-drop method using 24-well plates (Hampton Research VDX Greased Plates), 
with each reservoir well containing 900 µl precipitant solution. The purified protein 
solution was then mixed with the reservoir solution (3 µl each) on a siliconized glass 
circle cover slide (22 mm; Hampton Research) and the slide was used to seal the well. 
 As the broad screening produced crystals in the presence of polyethylene glycol 
(PEG), our fine screens centered on the addition of PEGs of various defined chain lengths 
(molecular weights ranging from 300 to 4000) under pH, salt and ionic strength 
conditions that produced crystals that were hexagonal from one viewing plane and 
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completely round as viewed perpendicularly. Specifically, combinatorial screens 
involved testing various buffers (50 mM of either sodium acetate pH 4.6, MES pH 6.5 or 
HEPES pH 7.5) and salts (100 mM of either NH4Cl, NaCl, CaCl2 or MgCl2). 
 Fine screens for optimal crystallization conditions of CTB
GPGP
MPR were 
conducted with 0.1 M HEPES pH 7.5 and varying concentrations of PEG 400. The best 
crystals appeared using a reservoir solution consisting of 34% PEG400, 0.2 M BaCl2, 
20% ethylene glycol. The hanging drop contained 1.5 µl reservoir solution, 0.5 µl 2M 
ammonium acetate, 2 µl protein sample and 0.41 µl 10% CYMAL-4 (yielding a final 
concentration of 0.74% or 2x the critical micelle concentration). 
 Fine screens for optimal crystallization conditions of CTBMPR were conducted 
with the choice buffer (50 mM HEPES pH 7.5) and focused on varying concentrations of 
choice PEGs (20–40% PEG 300, 5–20% PEG 3000 or 5–20% PEG 4000) in the presence 
of 100 mM NH4Cl, NaCl or CaCl2. In parallel, we conducted salt-concentration screens 
(50–200 mM) for NH4Cl, NaCl and CaCl2 in solutions that contained either 25% PEG 
300, 10% PEG 3000 or 10% PEG 4000. Finally, under the choice conditions of buffer, 
PEG and salt (50 mM HEPES pH 7.5, 25% PEG 300, 200 mM NH4Cl) we conducted an 
additive screen (Hampton Research Additive Screen), in which 96 different additives 
were added (1µl) to the individual drop well in a Qiagen CrystalEX 96-well Conical Flat 
Plate along with the protein and reservoir drop mixture, which consisted of 50 mM 
HEPES pH 7.5, 20% PEG 300, 10%(w/v) either glycerol, 2-propanol or CYMAL-4 and 
200 mM salt (either NH4Cl, NaCl or CaCl2). 
 Fine screens for optimal CTB
AAAA
MPR crystallization conditions were performed 
with 100 mM Tris pH 8.5 or 50 mM HEPES pH 7.5 while varying the concentrations of 
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either PEG 1000 (10–30%) or PEG 3350 (5–20%) in the presence of 200 mM of either 
NH4Cl, NaCl, CaCl2 or NH4HCO2. In parallel, salt-concentration screens of NH4Cl, 
NaCl, CaCl2 and NH4HCO2 from 0.05 to 0.2 M were set up with 100 mM Tris pH 8.5 or 
50 mM HEPES pH 7.5 and either 25% PEG 1000 or 10% PEG 3350. 
 Nano/microcrystals of CTB
AAAA
MPR were prepared by the ultrafiltration method. 
In this method, the supersaturated zone is reached by concentration of the protein by 
ultra- filtration while salt, precipitant and buffer concentrations remain constant. 300 µl 
purified protein (10 mg ml
-1
) was mixed with the same volume of precipitant solution 
consisting of 200 mM NH4HCO2, 30% PEG 3350, 10 mM CaCl2, 20 mM HEPES pH 7.5 
in a 100 kDa cutoff concentrator (Amicon Microcon YM-100). The setup was then 
centrifuged to reduce the retentate volume by half to regain the original protein 
concentration of 10 mg ml
-1
. Following overnight incubation, more precipitant solution 
was added (30µl) to further increase the yield of nano/microcrystals. Crystallization 
conditions are summarized in Table 2.2. 
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Table 2.2: Crystallization conditions 
Construct Condition 
CTB
GPGP
MPR 34% PEG 400, 0.2 M BaCl2, 20% ethylene glycol, 
0.5 M ammonium acetate, 0.74% CYMAL-4 
 
25–30% PEG 400, 0.2 M CaCl2, 0.1 M HEPES pH 7.5, 
0.3M galactose, 80–100 mM NaCl 
 
CTBMPR 25-30% PEG 300, 0.2 M CaCl2, 0.05 M HEPES  
pH 7.5, 0.02% βDDM 
 
25–30% PEG 300, 0.2 M NaCl, 0.05 M HEPES pH 7.5, 
0.02% βDDM 
 
25–30% PEG 300, 0.2 M NH4Cl, 0.05 M HEPES 
pH 7.5, 0.02% βDDM 
 
CTB
AAAA
MPR 8-12% PEG 3350, 0.1–0.2 M NH4HCO2, 0.01 M CaCl2, 
0.05 M HEPES pH 7.5, 0.02% βDDM 
 
CTB
AAAA
MPR 
nano/microcrystals 
30% PEG 3350, 0.2 M NH4HCO2, 0.01 M CaCl2, 
0.05 M HEPES pH 7.5, 0.02% βDDM 
 
 
 
Standard X-ray crystallography 
 
Characterization of the CTB
GPGP
MPR crystals was performed using synchrotron X-ray 
radiation on beamline 8.2.2 at the Advanced Light Source (ALS) at a wavelength of 1 Å. 
The crystals were flash-cooled in liquid nitrogen with a cryoprotectant solution (15% 
ethylene glycol, 50% PEG 400, 100 mM HEPES, 60 mM NaCl, 200 mM BaCl2, 150 mM 
imidazole, 0.017% βDDM) and diffraction data were collected at 100 K using an Oxford 
Cryostream. A total of 520 data frames were collected using 0.25° oscillations and an 
exposure time of 2.275 s per frame with an ADSC 315 detector. 
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Serial femtosecond nano/microcrystallography 
 
Nano/microcrystals were grown on-site and were analyzed by DLS prior to serial 
femtosecond X-ray nano/micro-crystallography using the high-energy free-electron laser 
at the Coherent X-ray Imaging (CXI) endstation of the Linac Coherent Light Source 
(LCLS) at SLAC National Accelerator Laboratory (Experiment L432, February 2012). 
This method allows data to be collected from hundreds of thousands of sub-micrometre 
nano/microcrystals (by spraying them across a pulsed X-ray laser beam) using X-ray 
snapshots so brief that they outrun radiation damage (for a review of the method, 
see(Spence et al., 2012)). Data were collected from a stream of fully hydrated 
nano/microcrystals. Experimental details of the beamline and data collection at CXI have 
been described by (Boutet & Williams, 2010) and (Boutet et al., 2012). A suspension of 
nano/microcrystals of CTB
AAAA
MPR (9.1 mg ml
-1
, total volume of 330µl) was supplied 
to the FEL X-ray beam using a gas-focused liquid microjet of 4µm diameter at 20°C, a 
temperature-controlled antisettling device and a flowrate of 10 µl min
-1
 using a gas 
dynamic virtual nozzle (Weierstall et al., 2012, DePonte et al., 2008, Weierstall et al., 
2008, Lomb et al., 2012). X-ray data were collected from the crystals at an energy of 6.3 
keV with a 50 fs pulse duration and an X-ray pulse repetition rate of 120 Hz. Diffraction 
patterns from protein crystals were identified and selected using the hit-finding program 
Cheetah (Barty et al., 2014), and indexing and merging was performed using CrystFEL 
(Kirian et al., 2011, White et al., 2012). 
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2.4 Results and discussion 
CTB
GPGP
MPR 
 
Previous work suggested that the immunogenicity of the MPR depends on its structural 
context, especially when fused to other proteins and peptides as is the case for CTB-MPR 
(Gach et al., 2011, Montero et al., 2012, Matoba et al., 2008, Matoba et al., 2011). Three 
different CTB-MPR fusion variants were designed that would differ in the linker peptide 
between the two fusion partners. 
 The original fusion protein that was described previously (Matoba et al., 2004) 
contained a GPGP linker. It is denoted here as CTB
GPGP
MPR (Figure 2.1b). Two 
additional variants were created as part of the present study with the GPGP linker either 
deleted (CTBMPR; Figure 2.1c) or replaced by a tetra-Ala linker (CTB
AAAA
MPR; Figure 
2.1d). To maximize expression levels in bacterial cells, all constructs reported here were 
devoid of a terminal histidine tag. Instead, we took advantage of a peculiarity of the CTB 
pentamer, preserved in the context of the fusion proteins, that allows it to specifically 
bind to metal-affinity resin (Dertzbaugh & Cox, 1998). Importantly, in the absence of a 
His tag only assembled pentamers can bind to the metal column (Dertzbaugh & Cox, 
1998). The fusion proteins were expressed as described by (Matoba et al., 2008) and were 
purified as described in §2 using the mild detergent βDDM for solubilization and in all 
further purification steps to facilitate crystallization efforts and biophysical analyses. 
 The purification scheme described above for CTB
GPGP
MPR fusion proteins 
resulted in >99% purity based on silver-stained polyacrylamide gels (Matoba et al., 
2008). As previously demonstrated by nondenaturing gel electrophoresis and by GM1 
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ganglioside ELISA (Matoba et al., 2008, Matoba et al., 2004), such protein preparations 
were highly homogeneous, consisting of primarily pentameric CTB
GPGP
MPR and only 
minor amounts of higher molecular-weight aggregates and monomeric protein. We were 
able to separate these various molecular forms by SEC–HPLC (Figure 2.2a). Oligomeric 
state assignment of the peaks was performed based on parallel SEC–HPLC runs with 
molecular-weight standards. This assignment was confirmed by resolving proteins in the 
pooled fractions corresponding to the peaks by SDS–PAGE under nonreducing 
conditions, which allows CTB to retain its pentameric organization (Figure. 2.2b; 
(Yasuda et al., 1998, Zrimi et al., 2010)). Taken together with the fact that that 
CTB
GPGP
MPR binds to the affinity resin, we conclude that the fusion protein is a stable 
pentamer. 
 Taking advantage of the presence of five tryptophan residues within the MPR 
domain (with one more within the CTB moiety), we subjected the proteins in the pooled 
fractions corresponding to CTB
GPGP
MPR pentamers to fluorescence spectroscopy (Figure 
2.2a, inset). The emission spectrum revealed that the Trp residues in the pentamers were 
exposed to the aqueous milieu (peak emission at 347 nm; (Ni et al., 2011, Reshetnyak et 
al., 2001)). The stability of the pentamers was demonstrated by the conservation of the 
Trp emission profile upon purification and concentration of the protein. 
 We screened a large number of crystallization conditions which included 
systematic variation of the protein concentration, pH, precipitant and ionic strength. 
Furthermore, we tested the reversibility of the crystallization conditions. The initial 
screens provided important information on the solubility of CTB
GPGP
MPR. The addition 
of galactose is essential for crystallization of the protein, while only irreversible 
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precipitation was observed in its absence. Reversible precipitation was observed at pH 7–
8 and at medium salt concentrations (50–250 mM). Crystallization was favored by the 
addition of divalent cations (e.g. Ca
2+
) over monovalent cations, and shorter-chain 
polyethylene glycol polymers (PEGs) were the preferred precipitants. 
 
 
Figure 2.2: CTB
GPGP
MPR oligomeric states (a) separation of aggregates and 
monomers from the pentameric CTB
GPGP
MPR protein by gel filtration on a Superdex 
200 column. Assembly status was estimated from parallel resolution of molecular-
mass standards (not shown). Inset, tryptophan fluorescence emission spectra of 
pentameric CTB
GPGP
MPR in pooled gel-filtration fractions corresponding to the major 
peak in (a). 1 (green), pentamers; 2 (blue), concentrated (Centricon 100) pentamers. 
Excitation was at 280 nm. (b) Proteins in the unconcentrated metal-affinity 
chromatography (MAC) eluate and in the size-exclusion chromatography (SEC) 
fraction corresponding to the main peak of the chromatogram in (a) were resolved by 
SDS–PAGE under nondenaturing (ND; no DTT and no boiling) and denaturing (D) 
conditions. Molecular-weight standards indicate that CTB
AAAA
MPR is organized into 
SDS-stable pentamers. The compact pentamers have a slightly higher electrophoretic 
mobility than expected based on their mass alone 
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 We found multiple 
Figure 2.3: The 
CTB
GPGP
MPR 
structure reveals the 
expected pentameric 
ring arrangement 
typical of wild-type 
CTB but not the 
structure of the MPR. 
Cartoon representation 
of the crystal structure 
of CTB
GPGP
MPR in 
two orientations: (a) 
top view, (b) side view. 
Each subunit is 
indicated by a different 
color. The C-terminus 
of one of the subunits is 
indicated in red. This 
region is shown in 
close-up in (c). (c) 
2FoFc electron-density 
map at a contour level 
of 1.5 of the C-
terminus of CTB in 
CTB
GPGP
MPR, which 
was phased with the 
pentameric CTB model 
(PDB entry 1jr0; 
(Pickens et al., 2002)) 
using molecular 
replacement (McCoy et 
al., 2007) Electron 
density can be seen 
beyond the terminal 
asparagine of CTB 
where the GPGP linker 
and MPR connect. 
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conditions where crystals formed. The crystals were grown in 0.1 M HEPES pH 7.5, 25–
30% PEG 400, 0.2M CaCl2, 0.3 M galactose, 80–100 mM NaCl at a protein 
concentration of 5 mg ml
-1
. The vapor-diffusion method (sitting drop) using ‘screw-cap’ 
plates (NeXtal) was used. Isolated crystals were cooled in liquid nitrogen in 
crystallization buffer containing 36% PEG 400 as a cryoprotectant. X-ray data were 
collected on beamline 8.3.1 at the Advanced Light Source (ALS). Most of the 50 µm 
crystals diffracted to about 20 Å resolution. The reflections were broad and anisotropic, 
indicative of the low order of the crystals in three dimensions. One unit-cell parameter 
was identified to be 45 Å. 
 Under slightly different crystallization conditions that included the presence of 
Zn
2+
 and lipids, crystals were observed that diffracted to a resolution limit of 2.3 Å. A 
full data set was collected from these crystals at the Advanced Photon Source (Table 2.3). 
Unfortunately, only the CTB region was ordered in the electron-density map, definitively 
demonstrating its pentameric nature (Figure. 2.3a and 2.3b). Weak electron density was 
observed that extended the C-terminus of CTB, but the structure of the MPR region could 
not be resolved in the crystals (Figure 2.3c). We hypothesized that this may be caused by 
the flexibility of the GPGP linker allowing the MPR region to assume multiple positions 
in the crystals. 
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Table 2.3: Crystallographic data for CTB
GPGP
MPR 
Values in parentheses are for the highest resolution bin. 
Wavelength (Å) 1.0 
Resolution range (Å) 59.48–2.10 (2.21–2.10) 
Space group R3:H 
Unit-cell parameters (Å/°) a = b = 174.39, c = 64.71, 
   α = β = 90, λ = 120 
Multiplicity 3.8 (3.8) 
Completeness (%) 99.95 (100.00) 
Mean I/σ (I) 6.68 (1.93) 
Wilson B factor (Å
2
) 30.72 
Rmerge 0.136 (1.302) 
R factor 0.214 (0.315) 
Rfree 0.249 (0.388) 
No. of atoms 4365 
No. of macromolecules 4100 
No. of waters 265 
No. of protein residues 515 
R.m.s.d., bonds (Å) 0.008 
R.m.s.d., angles (°) 1.08 
Ramachandran favored (%) 98 
Ramachandran allowed (%) 1.8 
Ramachandran outliers (%) 0.2 
Clashscore 8.52 
B factors (Å
2
)  
   Average 40 
   Macromolecules 39.9 
   Solvent 42.6 
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CTBMPR 
 
To test our hypothesis regarding linker flexibility, we created a second fusion protein 
variant in which the movement of the MPR domain was expected to be restricted by 
direct fusion of the MPR to the C-terminus of the CTB protein (CTBMPR; Figure 2.1c). 
 The purification procedure for the linker-less fusion protein CTBMPR followed 
the same scheme as outlined above except that elution was conducted batchwise with 
extended incubation periods (from 10 min to 16 h) and higher concentrations of 
imidazole (300 mM) were required to elute most of the protein from the column (Figure 
2.4). The molecular mass of the fusion protein as estimated based on SDS–PAGE 
resolution (Figure 2.4a) and immunoblotting (Fig. 2.4b) fitted the calculated value based 
on the sequence of the protein (17 kDa). 
 The homogeneity of the fusion protein in the pooled eluted fractions was tested by 
SEC–HPLC. This demonstrated that the preparation can be resolved into various peaks 
(Fig. 5). The results showed that unlike CTB
GPGP
MPR, the linker-less fusion protein 
exists in an equilibrium between several oligomeric molecular forms. Assignment of the 
oligomeric forms is based on the similarity in the elution volumes of the respective peaks 
to those of CTB
GPGP
MPR. Pentamers are not the predominant form of the linker-less 
CTBMPR protein, at least under our purification conditions. A substantial monomeric 
population is present alongside the pentamers in preparations obtained under similar 
purification conditions to those used in the purification of CTB
GPGP
MPR. In fact, since all 
of the protein loaded onto the SEC–HPLC column was specifically eluted from the 
metal-affinity column (and consequently must have been pentameric), it is likely that the 
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CTBMPR pentamer undergoes (partial) disassembly during manipulation following the 
metal-affinity chromatography stage. 
 
 
Figure 2.4: Affinity chromatography purification of CTBMPR. Protein samples 
from various steps in the purification process were resolved next to molecular-weight 
markers (lane 1) by SDS–PAGE and the gel was stained with Coomassie Brilliant 
Blue (upper panel). The whole cell lysate (lane 2) was spun down and the aqueous 
fraction (lane 3) was discarded. Membrane proteins were extracted from the pellet 
with βDDM (lane 4) purified over an affinity chromatography column. The 
flowthrough was collected (lane 5) and the column was extensively washed as 
described in the text (lane 6, first wash fraction; lane 7, last wash fraction). Elution 
required a larger volume of imidazole elution buffer to elute most of the protein bound 
to the column (lanes 8–10) than expected based on previous results with CTB 
GPGP MPR (Matoba et al., 2008). Immuno-blotting was performed on the same 
samples using monoclonal 2F5antibodies (lower panel) 
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 While gp41 is generally assumed to form trimers (Liu et al., 2008, Atilgan et al., 
2010) in its pre-fusion form, the involvement of the MPR domain in trimerization is less 
clear and evidence for alternative associations exist (see, for example,(Alfsen & Bomsel, 
2002)). This suggests that the equilibrium between the various oligomeric states is 
dynamic and may be explained by the competing tendencies of the CTB fusion partner to 
form pentamers, while the MPR fusion partner may push the equilibrium against 
pentamerization. 
Figure 2.5: Size-exclusion chromatography of CTBMPR shows it exists in several 
metastable oligomeric forms. Affinity-purified CTBMPR was resolved by SEC–
HPLC, yielding three major peaks probably corresponding to pentamers (fraction 8) 
and monomers (fraction 16). Fractions 21 and 23 did not contain appreciable amounts 
of protein and are likely to contain high concentrations of imidazole. The shoulder at 
the right of the pentamer peak (fraction 11) may represent the less stable intermediates 
tetramers and dimers. These fractions (numbered in red), alongside the original sample 
and a precipitate that formed in the original sample, were analyzed by SDS–PAGE 
followed by silver staining (inset). 
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 To investigate this hypothesis, we separately pooled the fractions corresponding 
to the monomeric and the pentameric forms of CTBMPR, concentrated them and 
analyzed them separately by SEC–HPLC (Figure 6). The pentamer appeared to be stable,  
 
 
Figure 2.6: The CTBMPR oligomeric state is affected by the concentration of the 
protein. SEC–HPLC fractions corresponding to the pentamer (a) and monomer (b) 
peaks (Figure 5) were subjected separately to a second SEC–HPLC purification. 
Absorbance is normalized to the highest peak 
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leading to a single peak with the same elution time. However, upon concentration of the 
monomer-containing fractions, most of the fusion protein was shown to elute as a fraction 
corresponding to the pentamer fraction, suggesting a reorganization of the protein into 
pentamers. These results provided support for our hypothesis that a dynamic 
concentration-dependent equilibrium exists between the various oligomeric forms of 
CTBMPR, where lower concentrations favor monomers and higher concentrations favor 
pentamer formation. 
 We carried out crystallization experiments of CTBMPR using the vapor-diffusion 
method and broad crystal screening, as described earlier, to identify conditions where 
crystals were able to form. Disappointingly, only a few conditions led to ordered 
precipitate or pseudo-crystals, and finer screens around the conditions did not produce 
three-dimensionally ordered crystals. A possible explanation is that the instability of the 
oligomeric states hinders the formation of crystals. 
 
CTB
AAAA
MPR 
 
Based on the results with CTBMPR, we designed a third variant of the CTB-MPR fusion 
protein, CTB
AAAA
MPR (Figure 2.1d), that links the two fusion partners with a short 
polyalanine peptide that is expected to assume an α-helical conformation (Oneil & 
Degrado, 1990). Our aim was to allow the fusion protein to assemble into stable 
pentamers by facilitating the ability of the MPR moieties to interact with each other while 
avoiding presumed disorder induced by the flexible GPGP linker. The SEC–HPLC 
purification profile resembled that for the CTB
GPGP
MPR variant (Figure 2.7a). The 
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formation of the pentamer, as verified by nondenaturing SDS–PAGE, was still 
concentration-dependent; however, the pentamer was much more stable for 
CTB
AAAA
MPR than for the linker-less construct CTBMPR (Figure 2.7b). 
 
 
 
 
 
Figure 2.7: CTB
AAAA
MPR resolved as an oligomer by SEC–HPLC. Pink line, the 
Talon column eluate (not concentrated). Blue line, 10 concentrated eluate sample. Red 
line, 20 concentrated eluate sample. Spectrograms were normalized to the highest 
peak. Inset: proteins in fractions corresponding to the main peak of the 20 
concentrated eluate chromatogram were resolved by SDS–PAGE under nondenaturing 
(ND; no DTT and no boiling) and denaturing (D) conditions. Molecular-weight 
standards indicate that CTBAAAAMPR is organized into SDS-stable pentamers. 
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Figure 2.8: DLS data of CTB
AAAA
MPR shows that it is monodisperse as a high-order 
oligomer. (a) DLS measurements were performed so that the size distribution in the 
sample was analyzed for 20 s and the measurement was repeated consecutively ten 
times. The moment-to-moment fraction of particles estimated to have a particular 
hydrodynamic radius is color-coded and shown as a heat plot (red, >90%; blue, none). 
The narrow vertical and red profile shown indicates high stability over the duration of 
the measurement and low polydispersity. Time: the total duration of the scanning 
session (200 s). (b) A distribution curve of particle-size frequencies gives a more 
quantitative evaluation of the polydispersity, with the mean  SD indicated next to the 
peak. The standard deviation of the size distribution is only 6% of the mean, 
indicating low polydispersity. 
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 We obtained the size distribution of the purified CTB
AAAA
MPR by dynamic light 
scattering (DLS) to determine whether the protein preparation was monodisperse (Figure 
2.8). At 8 mg ml
-1
, the hydrodynamic radius (Stokes radius, r) of the detergent-
solubilized protein (i.e. of the protein–detergent micelles) was determined to be 
6.2±0.4 nm. The polydispersity was estimated to be 6%, which is well below the 10–15% 
level considered as monodisperse (Proteau et al., 2010). Note that the DLS measurement 
in Figure 2.8 shows the direct scattering intensity, which is not corrected for the 
molecular mass of the particles to detect even traces of aggregates. As the increase in 
scattered intensity is proportional to r
6
, we calculated that the sample was highly 
monodisperse and contained less than 0.00001% aggregates. Since the exact geometry of 
CTB
AAAA
MPR is not known, a generic set of parameters was used assuming that the 
folded state is spherical with an estimated molecular mass of ~210 kDa, which includes 
the detergent bound to the protein. The DLS data indicated that CTBAAAAMPR may 
form a dimer of pentamers, corresponding to a molecular weight of 170 kDa for the 
protein, while a trimer of pentamers would be 250 kDa larger than the value calculated 
based on the DLS results. However, it is difficult to determine how much of the estimated 
molecular mass was associated with the detergent micelles around the hydrophobic 
regions of the protein. 
 A large set of crystallization experiments was carried out with purified 
CTB
AAAA
MPR similarly to that described above for the linker-less variant CTBMPR. 
Crystals were observed more frequently for CTB
AAAA
MPR than for CTBMPR, but 
despite the fact that CTB
AAAA
MPR appeared to be more stable and more homogeneous 
than CTBMPR, the crystal quality was still poor. Under most conditions, pseudo-crystals 
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were observed and were similar in shape to the CTB
GPGP
MPR crystals (Figure 2.9). The 
crystals shown in Figure 2.9a feature a hexagonal shape when viewed from the ‘top’, but 
are completely round when viewed from the side. X-ray diffraction patterns from these 
crystals show features of a hexagonal powder diffraction pattern, which may indicate that 
the crystals consist of stacks of two-dimensional crystals which are disordered in the third 
dimension. However, we noticed that crystal disorder seemed to be correlated with the 
size of the crystals, with larger crystals displaying more disorder. 
 
 
Figure 2.9: CTB
AAAA
MPR crystals form under different conditions of a fine screen. 
(a) 0.2 M ammonium formate, 8% PEG 3350. (b) 0.2 M ammonium formate, 5% PEG 
3350. (c) 0.2 M ammonium formate, 12% PEG 3350. (d) 0.1 M ammonium formate, 
10% PEG 3350 
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 Taking this into account, crystals were rapidly grown by a fast increase of the 
supersaturation state using ultrafiltration to concentrate the protein at a constant 
precipitant concentration (Figure 2.10). Most of the crystals were smaller than the 
shortest wavelength of visible light; they had the appearance of amorphous precipitates, 
with very small microcrystals also visible in the sample (Figure 2.10), and this mixture of 
small (1–2 mm) and very small (<1 mm) crystals will be referred to here as 
‘nano/microcrystals’. CTBAAAAMPR nano/microcrystals were grown on site at LCLS, 
characterized by DLS and SONICC and their diffraction quality was tested by the new 
method of serial femtosecond crystallography (SFX) on the CXI beamline at the LCLS. 
This beamtime was dedicated to the exploration of the use of SFX for structure 
elucidation of membrane proteins following the seminal work by (Chapman et al., 2011) 
and (Boutet et al., 2012). These articles provide detailed description of sample delivery 
and data collection that will only briefly be recounted here (see the review by(Spence et 
al., 2012)). Millions of X-ray data diffraction snapshots were collected from a stream of 
protein nanocrystals or microcrystals in their mother liquor at room temperature as they 
flow across the beam. Diffraction snapshots of individual crystals of CTB
AAAA
MPR were 
collected using X-rays pulses of extremely high intensity (10
9
 higher peak brilliance than 
the brightest third-generation synchrotrons). The 10–50 fs pulses are so brief that the 
diffraction of each nano/microcrystal is recorded before it is disintegrated. This diffract-
before-destroy principle (Barty et al., 2012) overcomes the X-ray damage problem in 
conventional crystallography and allows data collection from crystals that contain only a 
few hundred molecules (Chapman et al., 2011). The results from the LCLS beamtime 
were very promising, as we were able to grow crystals on site and detected the first  
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Figure 2.10: Nano/microcrystals of CTB
AAAA
MPR grown in 0.2 M ammonium 
formate, 30% PEG 3350 before (a) and after (b) filtering through a 20 mm filter. The 
crystals in (b) are shown at a higher magnification 
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single-crystal diffraction patterns from CTB
AAAA
MPR nano/microcrystals. While the 
larger crystals of CTB
AAAA
MPR were disordered in the third dimension, the 
nano/microcrystals are ordered in all three dimensions and show a low degree of disorder. 
We did not observe any anisotropy of the diffraction patterns even in the third dimension. 
This is particularly striking since the nano/microcrystals of the protein were grown using 
the same set of precipitants at initial higher concentration, therefore reaching the 
supersaturation and nucleation phase much faster than in the vapor-diffusion experiment 
leading to the larger disordered crystals. A single sort short run of the CTB
AAAA
MPR 
nano/microcrystals allowed us to collect 1006 patterns, most of which showed diffraction 
to 4–6 Å resolution and were successfully indexed (see two typical diffraction patterns 
and their indexed images in Figure 2.11; Table 2.4). From the indexed patterns, we were 
able to determine the space group and the unit-cell parameters. The crystals appear to be 
rhombohedral (consistent with point group R32 with unit-cell parameters a = b = c = 332 
Å, α = β = λ = 60°). There are only a few published examples of structures with space 
group R3 and a similar unit-cell parameter to that we observed here for the 
CTB
AAAA
MPR fusion protein. Interestingly, the three examples we could find in the PDB 
happen to be of viral origin. These PDB entries include the structure of Physalis mottle 
virus (PDB entry 1qjz;(Krishna et al., 1999)), with unit-cell parameters a = b = c = 294 Å, 
α = β = λ = 59.91°, and the structures of the Sesbania mosaic virus coat protein (PDB 
entry 1smv; (Bhuvaneshwari et al., 1995)) and its mutant (PDB entry 1x33; (Sangita et 
al., 2005)), with unit-cell parameters a = b = c = 291 Å , α = β = λ = 62°. 
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Figure 2.11: CTB
AAAA
MPR FEL diffraction pattern (a) Two CTBAAAAMPR 
diffraction patterns collected from nano/microcrystals on the CXI beamline at LCLS 
in February 2012. (b) Indexing of the diffraction patterns in (a). The yellow circles 
indicate the predicted positions of the reflections 
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Table 2.4: Crystallographic data for CTBAAAAMPR micro/nanocrystals 
 
Run time 10 min 40 s 
Total No. of raw frames 72767 
No. of crystal hits 1006 
Hi rate (%) 1.38 
No. of indexed patterns 55 
Indexing yielding (%) 5.46 
Unit cell parameters (Å,°) a = b = c = 332, α = β = λ = 60 
Space group R32 
 
 Since each diffraction pattern is a ‘still image’ and most reflections are partial, 
accurate determination of structure requires high redundancy of the data set, i.e. many 
recordings in the vicinity of each reflection, in order to provide angular integration across 
the Bragg condition. For example, the first near-atomic resolution structure of a protein to 
be determined using femtosecond crystallography contained more than 12,000 indexed 
diffraction patterns (Boutet et al., 2012). While the minimum number of single crystal 
hits that are required for structure analysis is currently unknown, the thousand reflections 
that we were able to collect with our very small sample size did not constitute a full 
native data set that could support structure determination; more data will have to be 
collected to this end. 
 It was surprising to see that the nano/microcrystals of CTB
AAAA
MPR (most of 
which are <1 mm) are ordered in three dimensions while the larger (100–300 mm) 
crystals grown with the same set of precipitants are completely disordered in the third 
dimension. We are currently screening conditions and applying seeding techniques to 
grow crystals of defined micrometer sizes from the nano/microcrystals for conventional 
X-ray data collection at synchrotron microfocus beamlines. The plan is to test the 
diffraction quality of crystals with target sizes ranging from 5 to 100 mm to determine up 
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to which size the crystals are still ordered in three dimensions, with the goal of 
identifying a ‘single-crystal threshold’ that may enable data collection at microfocus 
beamlines. We can then further optimize the crystal quality of the microcrystals by fine 
screening of the conditions, including the screening of additives. 
 NMR and crystal structures have been determined of small peptide derivatives of 
the MPR region that contain binding sites for neutralizing antibodies (Biron et al., 2005, 
Song et al., 2009, Pejchal et al., 2009) and the consensus is that this peptide can assume 
an α-helical conformation. Further structural information on the MPR region was 
obtained by studies involving an in vitro-assembled six-helix bundle consisting of 
separately produced peptide derivatives of gp41 (Shi et al., 2010) and a chimeric protein 
consisting of a series of gp41 peptides separated by linkers (Buzon et al., 2010). The 
conformations observed in these studies are very likely to represent the post-fusion form 
of MPR. However, the structure shows that the 2F5 binding site is deeply buried inside 
the three-helix bundle (Shi et al., 2010, Buzon et al., 2010) and therefore these constructs 
may not induce 2F5-like neutralizing antibodies. During the fusion process, large 
conformational changes must occur in gp41 that break the interaction between the trimers 
and expose the 2F5 antibody-binding site, thereby allowing 2F5 to block fusion and 
transcytosis; thus, a structure of the fusion-active form of MPR is highly desired. Our 
ultimate goal is to design an optimal CTB-MPR construct that can serve as a vaccine 
against HIV. Our design of the MPR fusion with CTB is based on the idea of a symmetry 
mismatch, where the pentameric oligomeric state of CTB hinders the formation of trimers 
of MPR and thereby stabilizes the MPR region of gp41 in its pre-fusion active form. 
While we present major strides in this work, further improvement of both the traditional 
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X-ray crystallography approach (including co-crystallization with neutralizing 
antibodies) and less-explored innovations such as serial femtosecond crystallography are 
needed to allow us to meet this goal. 
 This work presents a proof of principle that three-dimensionally ordered 
nano/microcrystals can be grown from a protein that had so far resisted growth of any 
macroscopic crystals that were ordered in three dimensions. Most remarkable is the fact 
that the SFX diffraction patterns clearly indicate that the nano/macrocrystals were single 
crystals, while macroscopic crystals grown with the same chemical compounds as 
precipitants showed the features of two-dimensional crystals stacked nearly randomly in 
the third dimension. Further enhancement of the quality of the nano/microcrystals by 
application of improved methods of nanocrystal growth (Kupitz et al., 2014) and the 
collection of a full data set from these crystals by serial femtosecond nanocrystallography 
would allow us to determine the structure of CTB
AAAA
MPR. 
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3.1 Abstract 
 
CTB
AAAA
MPR is a fusion protein consisting of the cholera toxin B subunit (CTB) and the 
membrane proximal region (MPR) of gp41, which is the transmembrane envelope protein 
of human immunodeficiency virus 1 (HIV-1). The two proteins are fused together with a 
tetra-alanine linker. It is a candidate vaccine component aimed at inducing the production 
  65 
of antibodies targeting the early steps of HIV-1 mucosal transmission. Here we report on 
crystallization experiments and preliminary X-ray crystallographic analysis of crystals 
formed from a solution of the fusion protein. The final goal of the study is to investigate 
the structure of CTB
AAAA
MPR with MPR in its fusion-active form to guide 
improvements of the immunogenicity of the fusion protein design.  A 1.9 Å data set was 
obtained from needle-like crystals grown from the monodisperse solution of 
CTB
AAAA
MPR. However, X-ray structure analysis revealed that the crystals contained 
CTB but no electron density was observed in the structure beyond the final residue of 
CTB suggesting that the MPR domain and alanine linker was cleaved. CTB was found to 
be arranged in a unique crystal packing and unit cell that has not been observed before for 
CTB nor any of its fusion proteins. The structure contains two unaligned CTB pentamers 
in the asymmetrical unit, which suggests that MPR was present during crystallization and 
influenced the crystal packing. Further investigation by monitoring crystallization on a 
day by day basis showed that the fusion protein is very stable under conditions that do not 
lead to formation of crystals, but is cleaved as soon as large well-ordered crystals are 
formed. 
 
3.2 Introduction 
 
Efforts to develop drugs and vaccines against acquired immune deficiency syndrome 
(AIDS) have prompted significant research efforts on the envelope glycoproteins of HIV-
1. The viral envelope consists of two glycoproteins: 1) gp41 is the transmembrane 
glycoprotein that contains an ectodomain largely responsible for the trimizeration of the 
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complex and 2) gp120 is an exterior glycoprotein which covers part of gp41. Both 
glycoproteins play an important role in viral transmission and infection (Wyatt & 
Sodroski, 1998). Although high mutation rates in HIV-1 lead to high antigenic 
variability, researchers have identified several well conserved regions of the envelope 
protein that are crucial to viral functions, which is reviewed in (Zolla-Pazner, 2004). One 
such region is the transmembrane-proximal region of the gp41. Although it is poorly 
immunogenic, many of the antibodies that bind to this region, such as 2F5, 4E10, and 
Z13, are broadly neutralizing against HIV-1 (Zwick et al., 2001, Zolla-Pazner, 2004). 
Residues 649-684 of gp41, which we termed MPR, play a crucial role in viral epithelial 
transcytosis by binding to glycosphingolipid galatosylcermide (GalCer) on the surface of 
epithelial cells and is transcytosed using a non-fusogenic mechanism (Bomsel, 1997, 
Alfsen et al., 2001, Alfsen & Bomsel, 2002). Antibodies (Abs) that target gp41, such as 
2F5 or secretory IgA, are present in mucosal secretions of people that have been highly 
exposed to HIV, but persistently test negative for HIV in their blood sera; these 
antibodies were shown to have high efficiency in blocking viral transcytosis (Devito et 
al., 2000a, Devito et al., 2002, Miyazawa et al., 2009, Tudor et al., 2009). These studies 
support the hypothesis that inducing Abs against MPR in the mucosal immune system 
may be an effective method to prevent viral entry into the body, as over 90% of global 
HIV transmissions occur across the mucosal surface (Kresina & Mathieson, 1999, 
Overbaugh et al., 1999). 
 To ensure efficiency, the ideal vaccine should contain components that target 
various steps of the viral transmission and infection process, especially in the early stages 
of the viral cycle to take advantage of viral vulnerabilities of the low founder viral 
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population and to minimize the establishment of systematic infection (Haase, 2010). The 
crucial involvement of MPR in these viral functions makes this domain a prime candidate 
for vaccine development. These findings led us to construct a fusion protein, consisting 
of the mucosal adjuvant CTB and MPR as a vaccine component aimed at inducing Abs 
that would target the step of viral transcytosis in the mucosal epithelial cells. The fusion 
protein has been shown to induce transcytosis by blocking anti-MPR antibodies in mice 
and rabbits (Matoba et al., 2004, Matoba et al., 2006, Matoba et al., 2008). However, the 
immune response of the MPR is overshadowed by the immuno-dominant CTB. 
 We began structural investigation of CTB MPR with the goal to understand the 
function of MPR and the viral infection processes it is involved in, and its interaction 
with the immune system as a fusion protein. Structural information could help us 
elucidate the immunogenicity of the fusion protein and enable designing even more 
immunogenic fusion proteins. We have recently published work on structural 
investigation of various CTB-MPR constructs with different linkers between the fusion 
partners (Lee et al., 2014). A flexible glycine-proline-glycine-proline linker proved to be 
too flexible for structure determination using X-ray crystallography as the electron 
density of the MPR region can be seen but is not resolved well enough for model fitting. 
Removing of the linker completely, so as to directly attach MPR to CTB, proved difficult 
for crystallization due to the instability of the pentameric oligomeric state. A third 
construct was designed using a more rigid tetra-alanine linker, which initially proved 
difficult for macroscopic crystal formation, however some promising data was collected 
on micro/nano-crystals using the X-ray free electron laser (XFEL); however the data set 
was only partial due to sample and XFEL beamtime limitations (Lee et al., 2014). 
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 In this report, we further investigated crystallization conditions that initially 
produced the micro/nano-crystals and optimized it for obtaining macroscopic crystals for 
structure analysis at Synchrotron X-ray sources. 
 
 
Figure 3.1:  gp41 and CTB
AAAA
MPR fusion protein (a) A schematic diagram of 
HIV-1 gp41. Fusion peptide (FR. Residues 512-539); fusion peptide proximal region 
(FPPR residues 528–539; N-terminal heptad-repeat region (NHR, residues 540–590); 
C-terminal heptad-repeat region (CHR, residues 628–661); membrane proximal 
external region (MPER, residues 662–684); membrane proximal region (MPR, 
residues 647–684, blue), transmembrane domain (TM, residues 685–705); 
cytoplasmic C-terminal domain (CTD, residues 706–856). The epitopes of 2 broadly 
neutralizing antibodies 2F5 and 4E10 are marked. (b) DNA construct for the 
expression in E.coli of the CTB
AAAA
MPR fusion protein based on elements of the 
pET-26b(+) expression vector.  P, T7 bacteriophage promoter, 5’UTR, upstream 
untranslated region; pelB, the periplasmic targeting sequence of pectate lyase B of 
Erwinia carotovora; CTB, cholera toxin B subunit; AAAA, tetra-alanine linker; MPR, 
the membrane-proximal region of gp41 protein of HIV-1; 3’UTR, downstream 
untranslated region; T, T7 terminator. (c) Amino acid sequence of fusion protein 
CTB
AAAA
MPR with expected molecular mass of 16.7kDa. The CTB domains are 
labeled orange followed by the tetra-alanine linker and the MPR regions labeled in 
blue 
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3.3 Materials and Methods 
Protein preparation 
 
The cloning of the gene encoding the CTB and the MPR649-684 with tetra-alanine linker 
(AAAA) between the two proteins (hereafter dubbed CTB
AAAA
MPR) shown in Figure 3.1 
has been described in previously published work (Lee et al., 2014). The gene was 
inserted into an expression vector derived from pET26B(+) (Novagen), which contains an 
N-terminal pelB signal sequence for periplasmic localization, to obtain the plasmid 
pTM646. The construct was verified by DNA sequencing. 
 The CTB
AAAA
MPR protein was overexpressed in Escherichia coli BL21 (DE3) 
cells following a protocol derived from previously published work for another variant of 
the fusion protein (Matoba et al., 2008, Lee et al., 2014). Modifications were made to 
optimize the protocol to improve the expression as well as reduce the viscosity of the 
detergent extract for purification purposes. 
 An overnight starter culture was grown in 50 ml lysogenic broth (Luria-Bertani 
medium, LB) at 37°C on a shaker set at 200 rpm.  A 1:200 dilution of the starter culture 
was used to inoculate 4 l expression cultures and grown to an OD600nm of 0.8 at 37°C. The 
expression of recombinant protein was then induced with isopropyl β–D-1-
thiogalactopyranoside (IPTG) at a final concentration of 0.3 mM at 37°C for 3h. The 
cells were harvested by centrifugation at 5000 g yielding approximately 2.5 g to 3.0 g of 
wet cell pellet per liter of culture and frozen at -80°C. 
 The cell pellets were then thawed on ice before being combined by resuspended 
in 80 ml of ice-cold phosphate buffer saline (PBS; 137mM NaCl, 2.7 mM KCl, 10mM 
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Na2HPO4, and 1.8 mM KH2PO4) supplemented with 1mM phenylmethylsulfonylfluoride 
(PMSF). Cells were lysed by passing three times through a microfluidizer (Microfluidics 
Microfluidizer) with the re-supplement of PMSF between the passes. The lysate was 
collected by centrifugation at 36,000 g and the supernatant was discarded. The insoluble 
fraction was washed once by resuspension in ice-cold PBS and centrifugation then frozen 
at -80°C. 
 The cell pellet, containing the membrane fraction was thawed on ice before 
resuspending in 60 ml of ice-cold buffer containing 500 mM NaCl, 20 mM bicine pH 8.0. 
A sonicator (Model 300 V/T Ultrasonic Homogenizer, Biologics, Inc.) was used to fully 
homogenize the solution by running 30 s on/off cycles at 20% amplitude until a 
homogenous suspension was obtained. 8 ml of a stock solution containing 10% (w/v) n-
dodecyl-β-D-maltoside (βDDM) was added to the homogenized solution and brought to a 
final volume of 80 ml using more ice-cold solubilization buffer for overnight 
solubilization at 4°C with agitation. 
 The detergent extraction solution was centrifuged at 36,000 g and the pellet was 
discarded. A gravity-driven column (Bio-Rad Econo-column) containing 40 ml of cobalt 
affinity resin (TALON, Clontech) was equilibrated with binding buffer (solubilization 
buffer supplemented with 0.05% βDDM). The detergent extraction supernatant was then 
loaded onto the column and washed with six bed volumes of binding buffer followed by 
ten bed volumes of wash buffer (50mM NaCl, 20mM bicine pH 8.0, 5 mM imidazole, 
0.05% βDDM) removing weakly bound proteins. Three bed volumes of elution buffer 
containing 50mM NaCl, 20mM bicine pH 8.0, 150 mM imidazole, 0.05% βDDM was 
used to elute the tightly bound proteins. The eluted fractions were pooled and then 
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concentrated to approximately 2mg ml
-1
 using 50kDa molecular-weight cutoff (MWCO) 
concentrators (Vivaspin 20, Sartorius Stedim Biotech). The concentrated solution was 
then subjected to size-exclusion chromatography (Superdex 200, GE Healthcare) in 
buffer consisting of 10 mM calcium chloride, 20mM 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) pH 7.5, 0.02% βDDM running at 0.5 ml min-1 shown in 
Figure 3.2. The protein elution was detected by absorption at 280 nm and manually 
collected to separate shoulders from main peaks. Only the main pentamer peak that eluted 
at minute 28 was used for crystallization experiments. The concentration of 
CTB
AAAAMPR preparations were determined spectrophotometrically using ɛ280 = 39380 
M
-1
cm
-1
. 
 
 
 
Figure 3.2: Size exclusion chromatograph of CTB
AAAA
MPR shows a dominate 
pentameric peak at minute 28 with a trailing shoulder that is discarded. The small peak 
at 42 minute corresponds to the monomeric fusion protein and imidazole from the 
metal affinity column elution buffer at minute 52. 
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SDS-PAGE and immuno-blot-analysis 
 
 SDS-PAGE gels for protein samples were done using tricine-based buffers and 
Bio-Rad Mini-PROTEAN Tetra Cell following procedures  based on the method 
developed by (Schagger, 2006) and adapted by Lawrence et al. (2011). SDS-PAGE for 
dissolved crystals was performed using the PhastSystem-High Speed Electrophoresis 
System (Pharmacia) using High Density PhastGels (Pharmacia) and PhastGel buffer 
strips (Pharmacia). After electrophoresis, the gels were subjected to silver staining 
(Lawrence et al., 2011) or processed for immunoblotting with monoclonal antibody 2F5 
or 4E10 (AIDS Reagent Program) or polyclonal anti-CTB antibodies (List Biological 
Laboratories, Inc.) following the protocol described in (Lee et al., 2014). The assembly of 
pentamers of the CTB
AAAA
MPR was monitored by enzyme-linked immunosorbent assay 
(ELIZA) using GM1 gangliosides to capture CTB pentamers and detected with 
monoclonal antibody 2F5 as previously described in (Matoba et al., 2008). 
 
Crystallization experiments 
 
CTB
AAAA
MPR protein in buffer from the size-exclusion chromatography was 
concentrated to 10 mg ml
-1
 for crystallization experiments using 100kDa MWCO 
concentrators (Millipore, Centricon). 
 Broad matrix screening was done using the Phoenix crystallization robot (Rigaku) 
with commercial screening kits from Qiagen and Hampton Research. The experiments 
were set up by sitting-drop vapor-diffusion method using MRC Crystallization Plates 
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(Hampton Research) that contained 96 wells and 2 drop chamber per well. The reservoirs 
were filled with 65 µl of precipitate solutions from the screening kits. In the drop well, 
the protein was mixed with the reservoir solution in 1:1 and 2:1 ratios, 100 nl protein plus 
100 nl precipitant solution and 200 nl protein plus 100 nl precipitant solution 
respectively.  
 Additional crystallization screening and optimization experiments were 
performed based on the condition that had previously produced micro/nanocrystals (Lee 
et al., 2014), which contained 200 mM ammonium formate, 30% polyethylene glycol 
(PEG) 3350, 10 mM calcium chloride, 20 mM HEPES pH 7.5 with the batch method 
described in (Lee et al., 2014). 
 The goal was to grow larger crystals suitable for conventional X-ray structure 
analysis using Synchrotron Radiation. These fine screening and optimization experiments 
were performed by the hanging-drop vapor-diffusion method using 24-well plates 
(Hampton Research VDX greased plates). The reservoir well contained 900 µl of 
precipitate solution and 3 µl of the protein sample was mixed with an equal volume of 
reservoir solution on siliconized glass covers slides before the wells were sealed. The 
plates were incubated in a 20°C incubator. The concentration of ammonium formate 
tested ranged from 50 mM to 500 mM, and the PEG 3350 concentration ranged from 5% 
to 30%. Calcium chloride was present to maintain the oligomeric stability of the 
CTB
AAAA
MPR pentameric fusion protein and HEPES for maintaining the pH, the 
concentration of both chemicals were used at low concentrations of 5-15 mM calcium 
chloride and 10-30 mM HEPES pH 7.5. 
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 After an incubation time of seven days at 20°C, thin needles were observed in 
several crystallization drops at PEG concentrations between 8-15% PEG 3350. After 
further optimization, large needle shaped crystals were grown. The condition that 
produced the best diffracting crystals contained 200 mM ammonium formate, 10 mM 
calcium chloride, 20mM HEPES pH 7.5, and 8% PEG. Please note that all the various 
concentration of PEG 3350 that have been used for the vapor diffusion experiments were 
with 10-25% lower than the initial conditions of 30% PEG established for the growth of 
the micro/nano-crystals for the serial femtosecond crystallography experiments. Figure 
3.3 shows results from a set of crystallization experiments where the PEG concentration 
was systematically varied. The results indicated that the concentration of PEG 3350 has a 
direct effect on the size of the needle-like crystals, where the increase in PEG 
concentration results in the decrease in crystal size. 
 The crystals were cryo-protected in a solution containing 0.3M ammonium 
formate, 15 mM calcium chloride, 30 mM HEPES pH 7.5, 50% PEG3350 and flash 
frozen in liquid nitrogen prior to X-ray data collection at the Advanced Light Source 
(ALS). 
 CTB
AAAA
MPR crystal seeding experiments were conducted using micro/nano-
crystals grown with batch method described in (Lee et al., 2014) using the microseeding 
method base on (Bergfors, 2003). The experiments were set up on a 24-well plate that 
contained 900 µl reservoir solutions and the protein solution was mixed in a 1:1 ratio (3 
µl to 3 µl) on the siliconized glass cover. A human hair washed with ethanol and rinsed 
repeatedly in deionized water was streaked through the micro/nano-crystal solution and  
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Figure 3.3: CTB
AAAA
MPR crystals of various sizes formed under different PEG3350 
concentrations. All conditions contained 200 mM ammonium formate, 10 mM 
calcium chloride, 0.02M HEPES pH 7.5, (A) 8% PEG3350; (B) 9% PEG3350; (C) 
10% PEG3350; (D) 11% PEG3350; (E) 12% PEG3350; (F) 13% PEG3350 
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placed in hanging drops before the wells were sealed. The condition that produced the 
crystal clusters contained 200 mM ammonium formate, 10 mM calcium chloride, 20mM 
HEPES pH 7.5, and 15% PEG3350. 
 
X-ray crystallography 
 
X-ray data on the needle-like crystals grown from the solution of CTB
AAAA
MPR was 
performed using synchrotron X-ray radiation on beamline 8.2.1 at the Advanced Light 
Source (ALS) in Berkeley at a wavelength of 1 Å. The best data set consisted of 390 
frames collected using 0.33° oscillation with an ADSC 315 detector (see table 3.1 for the 
data statistics). 
 Data integrating and merging was done using XDS (Kabsch, 2010). Scaling was 
performed using the CCP4 program suite AIMLESS (Evans & Murshudov, 2013). The 
space group was determined to be P212121 with unit cell dimensions of a=43.35Å, 
b=114.63Å, c=213.20Å and α=β=γ=90°. The structure was solved by molecular 
replacement using Phaser (McCoy et al., 2007) with a model derived by molecular 
replacement from the CTB structure in the PDB entry 1JR0 as the search model. The best 
solution showed that there are two CTB pentamers in the asymmetric unit (TFZ = 22.9 
and LLG = 20201). Primary refinement was done using CCP4 program suite REFMAC5 
(Murshudov et al., 2011) and further refinement was performed with PHENIX (Adams et 
al., 2010). All residues were in the in the allowed regions of the Ramachandran plot with 
98% in favored regions. Results of the data-processing and refinement statistics are 
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shown in Table 3.1. Structural representations were prepared with PyMOL (Delano, 
2002) and views from various angles are shown in Figure3.4. 
 
3.4 Results and discussion 
Cleavage of CTB
AAAA
MPR 
 
The X-ray structure analysis and data statistics of the needle-shaped crystals grown from 
the solution containing CTB
AAAA
MPR was very encouraging. The crystal featured the 
space group P212121 with unit cell constants of a = 43.35 Å, b = 114.63 Å, c= 213.20 Å, 
α = β = λ = 90°. The data sets could be evaluated to 1.9 Å resolution, with high 
completeness even in the highest resolution shell. The R-values were low with R-work of 
0.183 (0.252) and an R-free of 0.219 (0.308) (see Table 3.1 for full data statistics). The 
structure revealed the typical ring of wild-type CTB pentamer. The crystals contain an 
unusual packing of CTB not observed in any CTB crystals so far with two pentamers 
molecules in the asymmetric unit. However, no electron density was observed beyond the 
CTB domain. The structure is shown in Figure 3.5 (A-C). The packing of CTB in the 
crystals, shown in Figure 3.5 (D), visualize the extremely tight packing of the CTB 
molecules leaving very little room for MPR. To verify whether cleavage of the fusion 
protein had occurred, the crystals were retrieved from the cryo-loops after returning from 
ALS and analyzed with SDS-PAGE using the PhastSystem (Pharmacia). The crystals 
were dissolved 5 µl SDS sample buffer and compared with pre-crystallized sample from 
the same sample preparation batch. The expected size of CTB
AAAA
MPR is 16.7kDa and 
this is the molecular weight identified for the fusion protein in the pre-crystallization  
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Table 3.1: Crystallographic data for data collected from crystals grown from a 
solution containing for CTB
AAAA
MPR at ALS 8.2.1(Berkeley) 
Values in parentheses are for the highest resolution bin. 
Wavelength (Å) 1 
Resolution range (Å) 48.33-1.9   (1.97-1.9) 
Space group P 21 21 21 
Unit cell parameters (Å / °) a = 43.35, b = 114.63, c = 213.20, 
   α = β = γ = 90 
Total reflections 164002 (16588) 
Unique reflections 84204 (8404) 
Multiplicity 1.9 (2.0) 
Completeness 0.99 (1.00) 
Mean I/sigma(I) 6.42 (1.90) 
Wilson B-factor 24.42 
R-merge 0.058 (0.408) 
R-meas 0.082 (0.577) 
CC1/2 0.992 (0.687) 
CC* 0.998 (0.902) 
Reflections used for R-free 4116 (425) 
R-work 0.183 (0.252) 
R-free 0.219 (0.308) 
CC (work) 0.937 (0.841) 
CC (free) 0.927 (0.811) 
Number of atoms 8968 
Number of Macromolecules 8140 
Number of water 828 
Protein residues 1030 
RMS (bonds - Å) 0.008 
RMS (angles - degree) 1.09 
Ramachandran favored (%) 98 
Ramachandran allowed (%) 1.6 
Ramachandran outliers (%) 0 
Rotamer outliers (%) 3.3 
Clashscore 4.17 
Average B-factor 28.2 
Macromolecules B-factor 27.4 
Solvent B-factor 36.0 
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sample in Figure 3.4. However, the protein from the dissolved crystals shows a lower 
molecular weight band around 11.5kDa, which is the expected molecular weight of CTB 
without the MPR domain. 
 To confirm the result, we performed an immunoblotting experiment with 4E10 
antibodies (anti-MPR) which confirmed that the dissolved crystal sample does not 
contain MPR, while the polyclonal Abs against CTB showed activity with both the 
crystal and the pre-crystallization sample. We concluded that the fusion protein was 
cleaved between CTB and the alanine linker during the crystallization process so that the 
crystals do not contain the MPR domain and the alanine-linker. 
 
 
 
Figure 3.4: SDS-PAGE of dissolved CTB
AAAA
MPR crystal using the Phastsystem 
and a high density PhastGel. A molecular weight marker (Bio-Rad, Precision Plus 
Protein
TM
 Dual Color Standards) is shown in lane 1, followed by the dissolved 
CTB
AAAA
MPR crystals that were used for data collection at ALS in lane 2. Lane 3 
contained the positive control of the sample before crystallization and lane 4 is the 
negative control containing only the crystallization buffer. 
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 Even though the MPR has been cleaved and is not present in the crystals, we 
hypothesize that it contributed to the formation of the new crystal form of CTB. The 
majority of the CTB structures in the PDB are from crystals that feature the monoclinic 
C2 space group (Figure 3.6A) while the CTB structure in our crystal grown from a 
solution of CTB
AAAA
MPR showed an orthorhombic P212121 space group (Figure 3.6B). 
Cholera toxin has shown to form crystals in orthorhombic space groups, but these cases 
involved either mutations, crystallization with the A-subunit as AB5 complex (van den 
Akker et al., 1997) or feature CTB with ligands or inhibitors bound to the receptor sites 
of CTB shown in Figure 3.6C and 3.6D (Aman et al., 2001, Fan et al., 2001). 
Furthermore, the packing of CTB in our crystals is unique. Nearly all the CTB structures 
in the PDB contain only one CTB pentamer per asymmetric unit, while there are two 
CTB pentamer molecules per asymmetric unit side by side present in our crystals. The 
two pentamers are inverted and unaligned facing different planes as shown in Figure 
3.6B. 
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Figure 3.5: Structural 
representation of the 
protein-structure in the 
crystals grown from the 
solution containing 
CTB
AAAA
MPR. The 
structure was phased with 
the pentameric CTB model 
(derived from PDB entry 
1JR0) using molecular 
replacement. The structure 
shows two CTB pentamer 
molecules per asymmetrical 
unit. (A) Top view. (B) Side 
view with the C-terminus of 
one of the subunit marked, 
which is shown in close-up 
view in (C). (C) Electron 
density map at a contour 
level of 1δ of the C-terminus 
of CTB. No electron density 
can be seen beyond the 
terminal asparagine residue 
of CTB, which indicates that 
the crystal contain only the 
fusion partner CTB. (the 
figure was produced using 
the program PyMOL 
(Delano, 2002), (D) CTB 
asymmetric unit shown with 
20 Å surrounding in the 
crystal packing. Adjacent 
CTB molecules are shown in 
gray. 
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Figure 3.6: CTB crystal packing. Structures obtained from PDB and generated using 
PyMol (Delano, 2002). Each asymmetric unit is shown in green and symmetric mates 
in gray. (A) The most common CTB space group is C2. CTB molecules in the same 
column alternate facing opposite directions. The structure is generated using 1JR0 
(Merritt et al., 1994) All the CTB molecules crystallized with C2 space group show 
extremely similar packing arrangements. (B) CTB packing from CTB
AAAA
MPR 
crystals featuring the P212121 space group. There are two CTB molecules per 
asymmetric unit and they are facing opposite directions and are not aligned. (C) A 
CTB mutant with P212121 space group PDB ID: 1G8Z (Aman et al., 2001). CTB 
molecules in the same column faces the same direction however the molecule is 
turned nearly 90 degrees between the columns. (D) CTB complexed with m-
nitrophenyl-α-D-galactose shows the P212121 space group PDB ID: 1EE1 (Fan et al., 
2001) but with a different packing than our crystals grown from the protein 
CTB
AAAA
MPR. The CTB molecules next to each other are perpendicular to each 
other. 
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Daily observation of crystallization and crystal seeding 
 
In order to determine if the crystallization process induces the cleaving of the fusion 
protein, experiments were set up to observe the crystallization process day by day. With 
these experiments we tried to determine whether freshly grown crystals still retained the 
MPR domain and if the cleavage of the fusion protein was just an artifact from crystal 
age and freezing. Crystallization trials were set up using 24-well plates with all wells 
containing the same condition that produced the best diffracting needle-like crystals and 
the experiment was performed at two different temperatures, 20°C and 10°C. Whole 
crystallization droplets on the siliconized glass slide from two of the wells were harvested 
and frozen at -80°C each day. 
 For the experiment performed at 20°C, small round crystals were observed after 
three days and needle-like crystals appeared after the fourth day. A photo of the well on 
day 6 (last day) is shown in Figure 3.8. The analysis of the whole crystal drop on SDS-
PAGE showed cleavage of the fusion protein after three days coinciding with the 
formation of the first crystal. Figure 3.7 show the results of western-blot analysis with 
anti-MPR and anti-CTB antibodies. The results confirm that the uncleaved fusion protein 
binds to both types of antibodies while the cleaved product showed only binding to anti-
CTB antibodies, confirming that the alanine linker and MPR has been cleaved off. 
 The experiment was repeated at 10°C. Here crystal formation was observed after 
two weeks and showed the same results on silver-stain in Figure 3.9; the fusion protein is 
cleaved when crystals are forming in the hanging droplet. No cleavage takes place when 
the fusion protein is incubated for the same amount of time at the corresponding 
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temperature in the crystallization buffer where the PEG concentration has been reduced 
to 0 and 2% or the protein is just incubated in the isolation buffer. We concluded that the 
cleavage of the fusion protein is coupled with the crystallization of the fusion protein and 
it is not an artifact from crystal handling. 
 
 
Figure 3.7: Immunoblotting of day to day crystallization experiments. Lane 1 
represents the molecular weight marker (Bio-Rad, Precision Plus Protein
TM
 Western C 
Standards), followed by sample at time = 0 in lane 2; t = 1 day in lane 3; t = 2 days in 
lane 4; t = 3 days in lane 5; t = 4 days in lane 6; t = 5 days in lane 7; (A) Samples 
tested against monoclonal 4E10 (anti-MPR) antibodies. Signal was only detected at 
the band corresponding to uncleaved CTB
AAAA
MPR at 17kDa. (B) Samples tested 
against polyclonal anti-CTB antibodies. The signal was detected for both the 
uncleaved CTB
AAAA
MPR at 17kDa and the cleaved product at 11.5kDa. 
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Figure 3.8: Day 6 of daily observation crystallization experiment at 20°C. Small 
round crystals were formed on the third day while long needle-like crystals were 
observed on the fourth day. 
Figure 3.9: SDS-PAGE of daily observation crystallization experiment at 10°C. 
Std represents the molecular weight standard. Control represents the pre-
crystallization sample solution. Lane numbers correspond to the day number since 
crystallization experiment was set up. Small round crystals appeared after two weeks 
shown in the lane labeled 15 with the cleaved product. 
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 In previous work on CTB
AAAA
MPR, data on the micro/nano-crystals of the fusion 
protein were collected at the Linac Coherent Light Source (Lee et al., 2014). Although 
there was not enough data for structure determination, the space group and unit cell 
dimensions were completely different from the needle shaped crystals described here. 
The nanocrystals crystallized in the rhombic space group R32 with huge unit cell 
constants of a = b = c = 332 Å, α = β = λ = 60°. This unit cell is very rare in the pdb with 
only three virus structures reporting similar unit cell constants and space groups. We have 
reproduced the nanocrystals under exactly the same conditions as described in (Lee et al., 
2014) and analyzed the nanocrystals with SDS-PAGE. The result in Figure 3.10 shows 
that the MPR domain is present in these showers of micro/nano-crystals, i.e. the 
nanocrystals with the large rhombic space group contain the intact fusion protein. 
 
 
Figure 3.10: SDS-PAGE silver-stain of CTB
AAAA
MPR nanocrystal. Lane 1 
represents a molecular weight marker. Lane 2 represents the pre-crystallization 
solution. Lane 3 represents the nano-crystals. The signal is weak due to the low 
volume used and possible loss of protein on the concentrator during the batch method. 
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 We therefore explored if seeding with the nanocrystals of the intact fusion protein 
could induce the formation of larger crystals of the intact fusion protein with the rhombic 
space group. When these micro/nano-crystals were used for microseeding, it produced 
larger crystals in a clustered formation shown in Figure 3.11. However, upon examining 
the protein content of these clustered-crystals, the protein also showed auto-cleavage of 
the MPR domain. 
 In conclusion, we have determined that the cleavage of the fusion protein 
CTB
AAAA
MPR is coupled with the crystallization process leading to the formation of 
large well-ordered crystals of CTB in a new crystal packing.  Rapid crystallization of 
CTB
AAAA
MPR in form of nanocrystals through the batch method lead to crystals of a 
large rhombic space group which contained the full length fusion protein CTB
AAAA
MPR, 
but required a XFEL that produce X-rays more than a billion time brighter than a 
synchrotron(Fromme & Spence, 2011) to obtain diffraction (Lee et al., 2014). 
 Even though MPR is not present in the crystal structure of CTB in the space 
group P212121, it may have contributed to the crystallization as the crystals show a unique 
packing of CTB with two pentamers in the asymmetrical unit not aligned to each other. 
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Figure 3.11: CTB
AAAA
MPR crystal cluster obtained from seeding with micro/nano-
crystals view with two different polarized lens microscopes. 
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CHAPTER 4 
ADDITIONAL EXPERIMENTS, CONCLUSION, AND OUTLOOK 
4.1: N105A CTB
AAAA
MPR 
 
Unable to receive additional beamtime to complete our partial SFX data sets for 
CTB
AAAA
MPR at LCLS, we opted to create a new construct with the goal to make the 
fusion protein more resistant to cleavage. Self-splicing of proteins has been reported 
through the cyclization of asparagine residues into succinimide, a reaction that lead to the 
cleavage of the peptide bond (Clarke, 1994, Mathys et al., 1999, Shemella et al., 2007). 
Indeed, the last amino acid of CTB is an asparagine. The structure determined by X-ray 
crystallography of CTB crystallized from the solution of CTB
AAAA
MPR (see chapter 3) 
confirmed that the last amino acid that is visible in the electron density map is the 
terminal residue of CTB, which provided further evidence that the self-cleavage have 
occurred there.  
 Testing the hypothesis, we decided to design a new construct where we changed 
the asparagine residue into an alanine by site directed mutagenesis there by extending the 
poly-alanine linker, hoping to hinder the cleavage of the fusion protein. 
 
Mutation of Expression Vector 
 
We have attempted to perform site directed mutagenesis, where the pTM646 (expression 
vector for CTB
AAAA
MPR) was used as the template, using site directed mutagenesis kits 
(QuikChange and QuikChange II, Agilent), However the cloning has failed. We  
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Table 4.1: Oligonucleotides used as primers 
No. Name 5’-Sequence-3’ 
1 oTM850 GCCATTAGCATGGCAGCTGCGGCCGCGGCCTCCC 
2 oTM851 GGGAGGCCGCGGCCGCAGCTGCCATGCTAATGGC 
   
3 oTM856 ATGAAATACCTGCTGCCGACCGCTGC 
4 oTM857 CCCATTCGCCAATCCGGATATAGTTCCTCC 
 
contribute the problem to the extremely high GC-content of the flanking alanine residues 
(GCC and GCG codons) in the sequence region, as we could not obtain PCR products 
using the primers of the mutated sequence. A different set of primers (see table 4.1) were 
tested but the experiments were not successful, as the binding of the primers to each other 
was irreversible due to the high GC-content of the primers. 
 Switching to overlapping PCR (Aiyar et al., 1996), two PCR reactions were 
conducted to generate the mutation using oTM850/oTM851 mutational primers and 
oTM856/oTM857 end primers that are located upstream and downstream of the gene. In 
reaction I, oTM851 and oTM856 were used to generate the PCR fragment upstream of 
the mutation, and reaction II using oTM850 and oTM857 to generate the PCR fragment 
downstream of the mutation with overlapping at the mutation. The two fragments were 
then extracted from the gels and joined together in a 3rd
 
PCR reaction using the end 
primers oTM856 and oTM857 to produce the full length mutational gene. The resulting 
PCR product was treated with NcoI–BlpI restriction digestion then ligated into NcoI–BlpI 
digested pET-26b(+) vector (see Figure 4.1). The vector was electroporated into DH5α 
cell lines and grown overnight. The colonies were screened for CTB-MPR by colony 
screening PCR. The resultant positive colonies were further tested for the desired 
mutation by isolating plasmids followed by DNA sequencing of the region of interest  
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using primers oTM 856/oTM 857. Upon confirmation of the desired clone, the plasmid 
(named as pTM 922), was electroporated into BL21 cell lines. 
 
Expression and purification 
 
The initial expression and purification of N105A CTB
AAAA
MPR construct following 
procedures similar to the protocols established for CTB
AAAA
MPR and described in 
Chapter 3. 
 However, problems occurred during the metal affinity chromatography 
purification step. The protein does not bind strongly to the cobalt-affinity column and the 
Figure 4.1: PCR products of N105A mutation (a) DNA standard (lane 1), Reaction I 
product (lane 2-3), positive control template (lane 4) Reaction II product (lane 5-6). 
(b) DNA standard (lane 1), PCR product with 50ng of each Reaction I and II (lane 2-
3), PCR product with 100ng of each Reaction I and II (lane 4-5). (c) DNA standard 
(lane 1), NcoI–BlpI digestion reaction (lane 2), undigested control (lane 3) 
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vast majority of the protein was lost in the flow through and washes. Only extremely 
small amounts of the protein N105A CTB
AAAA
MPR was detected in the fractions that 
were eluted with imidazole elution. The protein band was not even detected with silver 
staining and was barely visible on immunoblots against CTB and MPR (Figure 4.2 a). 
 The binding of fusion protein to the Talon metal affinity column solely depends 
on the natural pentameric formation of CTB. This is the reason why CTB and its fusion 
proteins can be isolated with cobalt-affinity chromatography without an HIS-tag 
(Dertzbaugh & Cox, 1998). The finding that N105A CTB
AAAA
MPR does not bind to the 
cobalt-affinity column indicates that the additional alanine may destabilize the 
pentameric structure of CTB. The low concentration of the eluted protein will further 
destabilize the pentameric structure as the formation of CTB oligomers is dependent on 
the concentration of the protein (Yasuda et al., 1998). 
 The protocol was modified by using terrific broth (TB) for cell growth instead of 
the LB medium. TB is a rich growth medium and it has been shown in the literature to 
increase the cell density and protein concentration in over-expression experiments 
(Tartoff & Hobb, 1987). Cells were grown at 37°C until an OD600nm of 0.6 was reached. 
Expression was induced at 25°C with 1 mM IPTG and cells were grown overnight after 
induction. The wet cell mass yielded from a one-liter TB culture was increased by a 
factor of 4. Approximately 10 grams were harvested in contrast to a yield of only 2.5 
grams per liter for the LB culture. The cells were lysed with a microfluidizer 
(Microfluidics) and the isolated membrane pellet was frozen at -80°C. 
 The detergent extraction buffer volume was also decreased from 80 ml to 50ml 
per 10 grams of wet cell mass. We anticipated to obtain higher concentration of N105A 
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CTB
AAAA
MPR protein using this procedure, but we were aware of the fact that there 
might be a trade-off as with a lower volume of the detergent containing solubilization 
buffer we may not solubilize all the proteins possible. A second detergent extraction step 
was performed to examine the cell pellet of the first detergent extraction step. The goal 
was to check if it is possible to extract additional N105A CTB
AAAA
MPR protein. 
Although additional N105 CTB
AAAA
MPR can be detected in the second extraction, the 
concentration proved to be not high enough for significant binding to the metal affinity 
column. 
 Further purification continued using the detergent extracts described above. The 
target protein was traced through purification using immunoblot as shown in Figure 4.2. 
The higher protein concentration led to a significant reduction in the protein loss in the 
Talon flow through and washes (Figure 4.2 lanes 4 and 5) and the protein could be eluted 
from the column with imidazole (lane 7).  The large improvement in binding and 
isolation is evident from the comparison of the protein yields achieved in the original 
protocol (a, lanes 7-9) and the modified protocol (b, lane 7). 
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Figure 4.2: Extraction and Talon purification of N105A Western blots with 2F5 
monoclonal Ab against gp41. (a) Purification using same procedure as CTB
AAAA
MPR 
in LB media. Showing whole cell lysate (lane 1), aqueous fraction (lane 2), detergent 
extraction (lane 3), Talon flowthrough (lane 4), washes (lane 5 and 6), elutions (lane 
7-9). (b) Purification using TB media and reduced detergent extraction volume. Whole 
cell lysate (lane 1), aqueous fraction (lane 2), first detergent extraction (lane 3), 
second detergent extraction (lane 3*), Talon flowthrough (lane 4), washes (lane 5 and 
6), elution (lane 7) 
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 The sample from the Talon elution was concentrated 20x using 50 kDa molecular-
weight cutoff (MWCO) concentrators (Vivaspin 20 VS2031, Sartorius Stedim Biotech) 
and loaded on a SuperDex200 column for size-exclusion chromatography (SEC) with the 
same running buffer as described for the CTB
AAAA
MPR experiments in chapter 3.  The 
chromatogram is shown in Figure 4.3. The peak intensity for N105A CTB
AAAA
MPR was 
considerably lower than CTB
AAAA
MPR and the chromatogram indicated the presence of 
aggregates. The protein compositions of the pentamer peak along with its shoulders were 
examined by SDS-PAGE. The results (insert in Figure 4.3) confirmed that the main peak 
and its shoulders all contained the fusion protein. 
 
 
Figure 4.3: Size-exclusion chromatography of N105A shows an aggregation peak 
shoulder before the elution of the main pentamer peak. The peaks fractions were 
examined by SDS-PAGE shown in the inlet. Lane 1 is a molecular standard and each 
of the lane numbers corresponds with the marked fraction number indicated on the 
chromatogram.  
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 The pentamer peak was collected from four runs of SEC and the corresponding 
fractions containing out fusion protein were pooled together.  The concentration was 
determined spectrophotometrically using the molar extinction coefficient of ɛ280 = 39380 
M
-1
cm
-1 
(calculated with the ProtParam web application; web.expasy.org/protparam/), 
and concentrated to a final concentration of 10 mg/ml
 
using 100 kDa MWCO 
concentrators (Amicon Centricon YM-100). Dynamic light-scattering measurements 
were performed using a NaBiTec GmbH setup. The DLS instrumental setup combines 
the SpectroSize 302 DLS instrument (Molecular Dimensions) with an S6D microscope 
(Leica) and an IR camera and allows DLS measurements of concentrated solution in 
drops as small as 0.5 microliter. The DLS measurements of the protein sample were 
performed in a 3 µl hanging drop using a 24-well crystallization plate (VDX Greased 
Plate, Hampton Research) covered with siliconized-glass circular cover slides (22 mm; 
Hampton Research). The well itself was filled with 600 µl SEC running buffer. Prior to 
the measurement, the protein solution was centrifuged (1,000 g, 10 minutes at 4°C) to 
remove any dust particles. During the measurement, the temperature was set to 20°C. Ten 
consecutive measurements, with an integration time of 20 seconds each, were averaged. 
An estimate of the hydrodynamic size was obtained with the instrumental software using 
the following parameters: refractive index 1.33, viscosity 1.006, shape factor 1.0, 
hydrated shell 0.2 nm.  
 At 10 mg ml
-1
, the hydrodynamic radius (Stokes radius, r) of the detergent-
solubilized protein was determined to be 7.56±0.45 nm. The results of 7 DLS 
measurements are shown in Figure 4.4. The left plot shows a graphic representation of 
the size distribution of particles from each of the 7 runs (each time point on the Y-axis 
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represents one run, the X-axis indicates the Stokes radius determined from each of the 
runs). The right plot shows the direct scattering intensity, which is not corrected for the 
molecular mass of the particles to detect even traces of aggregates. Both plots indicate 
that the sample is highly monodisperse as a high molecular weight oligomer. The 
molecular weight determined from the DLS experiment is 343.3 kDa . 
 
 
 
 
 
 
Figure 4.4: DLS data of N105A CTB
AAAA
MPR shows that it is monodisperse at 
10mg/ml and forms an high-order oligomer. (left) The size distribution of particles 
determined from each of the 7 DLS runs. The plot shows the particular hydrodynamic 
radius determined from each run (indicated by the time line on the Y-axis). The 
fractions of particles of a particular size are shown color-coded and as a heat plot (red, 
>90% of particles; dark blue, none). The narrow vertical red profile indicates high 
stability of size distribution over the duration of all 7 measurements indicative of a 
low polydispersity. (right) The distribution curve of particle-size frequencies gives a 
more quantitative evaluation of the polydispersity, with the mean Stokes radius and its 
error margin indicated next to the peak. 
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Crystallization experiments 
 
Several broad combinatorial crystallization screens were setup using commercial 
screening kits from NeXtal and Hampton Research with the vapor diffusion technique. 
Screening was performed using 96-well plates (Qiagen CrystalEX 96-well Conical Flat 
Plate) with the sitting-drop method, where each reservoir well contained 100 µl 
precipitant solutions. The purified protein solution was then mixed in a 1:1 ratio (1 µl:1 
µl) with the reservoir solution in the sitting-drop well. 
 However, no crystal formation was observed and the majority of the wells showed 
amorphous precipitates. Precipitate was also observed after five days storing at 4°C in the 
concentrated protein sample at 10mg ml
-1
 without the addition of precipitate solution. We 
examined the precipitates that formed without the addition of precipitate solution with 
SONICC for nano-crystals but have detected no signal, we therefore assumed that the 
precipitates were very likely amorphous and not nano-crystalline. The same precipitates 
were further examined with SDS-PAGE and the SDS gel. The results shown in Figure 4.5 
showed that the precipitate showed cleavage of the N105A CTB
AAAA
MPR fusion protein. 
The concentrated sample from SEC clearly shows the molecular weight of the protein to 
be approximately at the expected 17kDa (Figure 4.3 insert), however, the precipitate 
formed without addition of precipitate solution ran well below the 15kDa marker and 
correspond to the molecular weight of CTB only at around 11.5kDa. 
 This result indicates that the cleavage of the fusion protein is NOT auto-catalyzed 
by the terminal asparagine residue. 
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4.2: Conclusion 
 
Our studies of the different variants of the CTB-MPR fusion protein with different 
linkers, we have revealed differences in their biophysical characteristics. Crystallization 
of the different fusion protein was very challenging possibly due to the symmetry 
mismatch between the pentameric CTB and the trimeric MPR.  Protocols for the 
purification of all constructs has been established and optimized for each of the 
individual variants of CTB-MPR. Crystallization experiments led to the determination of 
growth conditions for the different variants of the fusion protein and several diffraction 
data sets and protein structures were obtained. 
Figure 4.5: SDS-PAGE of N105A Precipitate: Molecular weight standard (lane 1) 
and the protein precipitate (lane 2). It shows the molecular weight of the precipitate to 
be below 15kDa, corresponding to the approximate molecular of a cleaved product 
that only contains CTB at 11.5kDa. 
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 While the CTB
GPGP
MPR formed crystals of the intact fusion, the electron density 
beyond the CTB was not well defined, most likely due to the flexible linker, leading to 
difficulties to fit a structure model of MPR into the electron density map. The removal of 
the linker compromised the pentameric state of CTB and crystallization proved to be 
difficult to achieve. Only round pseudo-crystals that only produced powdered diffraction 
were observed. A more rigid tetra-alanine linker seems to have re-stabilized the CTB 
pentamer. However, the macroscopic crystals grown from CTB
AAAA
MPR showed 
cleavage of the poly-alanine linker and MPR from CTB during the formation of the 
crystals. 
 The micro/nanocrystals of CTB
AAAA
MPR contained the intact fusion protein, but 
only a partial data set has been collected at the Free Electron Laser and we are unable to 
complete the data set due to the severe limitations in beamtime at the X-ray FEL at 
LCLS. We will apply again in May 2015 for protein screening beamtime to collect a 
complete data set for structure determination of CTB
AAAA
MPR. 
 The large difference in the space group and unit cell size between the data 
collected from the large crystals that contained only CTB and the nanocrystals of the 
intact fusion protein for which data have been collected by serial femtosecond 
crystallography highlight significance of serial micro/nanocrystallography for difficult to 
crystallize proteins especially membrane proteins. 
 The diffraction data that were gathered from the micro/nanocrystal contained the 
intact CTB
AAAA
MPR while macroscopic crystals were either unordered and gave only 
powder diffraction or contained only the cleaved product, i.e. the structure consisted of 
CTB-only. 
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 The cleavage was originally attributed to the presence of the asparagine residue as 
the last amino acid of CTB as it has been reported in the literature that asparagine can 
self-cyclize into succinimide which is a common “protein splicing” technique in bacteria 
(Clarke, 1994, Mathys et al., 1999, Shemella et al., 2007). However, the asparagine 
proved to be not the cause of cleavage as the mutant protein N105A CTB
AAAA
MPR that 
was isolated after a long elaborate process of cloning and protein isolation optimization 
showed similar cleavage as the original CTB
AAAA
MPR construct. 
 Independent results with a different fusion protein (MBP-MPR-TM) indicate that 
MPR with an alanine linker might be highly prone to self-cleavage (Gong, 2014). The 
cleavage of both CTB
AAAA
MPR and N105A CTB
AAAA
MPR is highly similar to the 
situation where cleavage of a fusion protein that consisted of maltose binding protein 
(MBP) fused with the membrane proximal region and transmembrane domain of gp41 
(MPR-TM) was observed. In this construct, cleavage was observed when MPR-TM and 
MBP were linked with a triple alanine linker (Gong, 2014). The cleavage could be 
triggered when MPR is being attached to a large soluble protein with a rigid alanine 
linker. 
  The cleavage problem might be overcome by the use of micro/nanocrystals, 
which contain the full length fusion protein. This showed that the MPR is initially present 
in the tiny crystals with the large rhombic unit cell. Macroscopic crystal formation is then 
triggering cleavage of the fusion protein leading to the formation of larger crystals with a 
small orthorhombic unit cell that only contains CTB. 
 However, the initial presence of MPR may contribute to the crystal formation as 
the structures of the cleaved CTB protein shows a different space group and unit cell 
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parameters compared to the native fusion partner alone, both for the CTB and MBP 
fusion proteins. 
 Although the structure of the fusion protein of MPR with CTB was not solved, 
this work has elucidated new information on the fusion protein and very valuable 
knowledge was gained on self-cleaving process induced by crystallization that may have 
a huge impact on future studies not only of MPR but also other fusion proteins of 
membrane or membrane attached proteins. The work sets the foundations for the 
structure determination of various CTB-MPR variants of potential HIV vaccines and 
shows the significance of the new method of SFX for difficult to crystallize proteins. 
 
4.3: Outlook 
 
The final medicinal goal of the project is to develop a HIV-1 vaccine component that 
induces the production of Abs that can block the transcytosis of HIV-1 across the 
epithelial membrane. For the past few years our work has been focused on the structure 
determination of fusion proteins of the membrane proximal region of the HIV membrane 
protein gp41. New CTB-MPR constructs were produced with the purpose of structure 
determination, however so far only few new immunization experiments were performed 
with these constructs. Although the different variants proved to be difficult for structural 
determination with crystallography, they could be very useful for immunology.  
 It would be interesting to see the effects of the different linkers on CTB-MPR 
have on the immunization response as previous immunization experiments only explored 
the first CTB
GPGP
MPR construct. The constructs CTBMPR and N105A CTB
AAAA
MPR 
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might be especially interesting targets for immunization. The results have shown that it 
forms a stable pentamer at high concentrations but the pentameric oligomeric state is 
unstable at lower concentrations. The major difficulty in the previous immunization 
experiments with CTB-MPR was the fact that after initial antibody production against 
MPR and CTB, boosting only further increased the immune response against CTB. 
CTBMPR and N105A CTB
AAAA
MPR open the possibility to destabilize the CTB part of 
the construct in vivo as the dilution of the protein after injection may lead to the 
disassembly of the CTB pentamer which may then be less immunogenic thereby 
increasing the chances for formation of Abs against MPR. 
 The goal of structure determination of CTB-MPR should also continue using the 
SFX method. The diffraction from LCLS showed great promise and should be further 
pursued. With the availability of additional XFEL instruments worldwide and additional 
beamlines at the current two XFELs in Stanford and at SACLA in Japan, it may be 
possible to receive additional beam time for the CTB-MPR project and collect a full data 
set. 
 From the structural point of view, we should also explore the structure of gp41 
beyond the MPR region. Currently most of the published structures of gp41 contained 
only parts of the ectodomain of gp41 (Chan et al., 1997, Melikyan et al., 2000, Shi et al., 
2010, Pancera et al., 2014, Reardon et al., 2014), and limited structure information of the 
transmembrane domain or c-terminal domain has been published. These domains of gp41 
may offer additional information in the viral infection cycle of HIV-1. 
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